# Medical Question & Answer

**Sample ID**: 6a47a4d1-227a-b9a8-e627-f8e95c5ee2f2
**Dataset Index**: 336562

---

## Question

What is the recommended dosage for: Treatment of ocular pain and inflammation in adults after corneal refractive surgery?

---

## Answer

> Let's see… What do we have here? The user is asking about the recommended dosage for treating ocular pain and inflammation in adults after corneal refractive surgery. Let's break this down step-by-step. First, I need to think about which medications are actually FDA-approved for this specific indication. Then, I should verify the exact labeled dosing, frequency, and duration for each agent. Next, I will consider how procedure type (PRK vs LASIK vs SMILE) influences regimen choices. After that, I should review safety nuances and monitoring. Finally, I will synthesize a concise, clinically actionable recommendation with caveats and alternatives where appropriate.

> Let me first confirm the indication and the agents involved. The FDA-approved indication for ocular pain and inflammation after corneal refractive surgery applies to topical NSAIDs, specifically ketorolac tromethamine ophthalmic solution 0.4% (Acular LS), and diclofenac sodium ophthalmic solution 0.1% for temporary relief of pain and photophobia in this setting, whereas other NSAIDs like bromfenac and nepafenac are indicated for post-cataract inflammation and pain rather than corneal refractive surgery per se, so I need to be careful not to overextend their labeled use here [^111wHCps] [^116NpesN].

> Now, I should verify the labeled dosing for ketorolac 0.4%. The FDA labeling directs one drop into the operated eye four times daily as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery, with clinical trials demonstrating superiority over vehicle for pain and burning/stinging after PRK, which supports this regimen as the reference standard for this indication [^114FUFQX] [^111uS1HR] [^1154LUBg].

> Wait, let me verify the diclofenac 0.1% regimen because I initially recalled it as 1–2 drops four times daily for 3 days; hold on, I should double-check the label. The FDA labeling indicates diclofenac sodium ophthalmic solution 0.1% is indicated for temporary relief of pain and photophobia after corneal refractive surgery, but it does not specify a precise number of drops or a fixed duration, so practice commonly uses 1–2 drops QID for about 3 days, yet I must emphasize this is off-label dosing and should be individualized to patient response and surgeon preference [^notfound].

> Next, I should review how procedure type modifies regimen selection. For PRK, where epithelial healing drives pain, NSAIDs are particularly important and a 4-day QID ketorolac course is standard, often alongside a bandage contact lens and a topical corticosteroid taper to mitigate inflammation and haze risk; for LASIK, pain is typically less intense, so a shorter NSAID course or even single-day use may suffice in many cases, though some surgeons still use 2–4 days of an NSAID for comfort; for SMILE, pain is generally milder and NSAID use is often minimal or omitted unless symptoms warrant, again reflecting surgeon discretion rather than a mandated protocol [^116XXiiN] [^113XYcnH].

> I need to ensure safety is addressed. NSAIDs can cause corneal adverse effects including epithelial defects, ulceration, and melting, particularly with prolonged use or in patients with epithelial compromise, so duration should be limited to the shortest effective course and patients should be counseled to report pain, redness, photophobia, or visual changes promptly; transient stinging or burning on instillation is common with ketorolac, reported in up to 40% in trials, and is usually self-limited [^114JWEKb] [^114FUFQX] [^1154LUBg].

> Hold on, I should verify alternatives and adjuncts. Although bromfenac and nepafenac are not FDA-labeled for corneal refractive surgery pain, some clinicians use bromfenac once daily off-label for comfort and anti-inflammatory effect, balancing potential benefits against the lack of regulatory endorsement; corticosteroids are commonly co-prescribed to control inflammation after refractive surgery, with loteprednol gel 0.5% or suspension 0.5% frequently used QID for about 1–2 weeks with a taper, and difluprednate 0.05% QID for 2 weeks followed by BID for 1 week is another option, though steroid selection and taper should be individualized and IOP monitored [^1125u8pF] [^111558yk] [^113mZcFg].

> Let me synthesize the bottom line. For adults with ocular pain and inflammation after corneal refractive surgery, the most defensible, evidence-based regimen is ketorolac tromethamine ophthalmic solution 0.4% one drop into the operated eye four times daily as needed for up to 4 days, with consideration of diclofenac sodium ophthalmic solution 0.1% 1–2 drops QID for about 3 days as an alternative, recognizing that diclofenac's dosing is not precisely specified on label and should be tailored to response; procedure-specific adjustments and co-therapy with a topical corticosteroid are common, and all NSAID use should be time-limited with close follow-up for adverse effects [^114FUFQX] [^111uS1HR] [^1167XJYK] [^116XXiiN].

---

The recommended dosage for treating ocular pain and inflammation in adults after corneal refractive surgery is **ketorolac tromethamine 0.4% ophthalmic solution, 1 drop in the operated eye 4 times daily as needed for up to 4 days** [^114FUFQX] [^111uS1HR]. This regimen is supported by FDA labeling and clinical trials showing significant reductions in pain and burning/stinging after PRK [^1154LUBg]. Alternative NSAIDs such as diclofenac 0.1% (1–2 drops QID for 3 days) [^113iJL8b] or bromfenac 0.09% (1 drop BID) may be used off-label, but ketorolac is the **preferred first-line agent** for this indication [^114FUFQX]. NSAIDs should be used short-term only, with close monitoring for corneal toxicity and delayed healing [^114JWEKb].

---

## Recommended dosage and administration

- **Medication**: Ketorolac tromethamine ophthalmic solution 0.4% (Acular LS) [^114FUFQX].
- **Dosage**: 1 drop in the operated eye 4 times daily (QID) [^111uS1HR].
- **Duration**: Up to 4 days following corneal refractive surgery [^114FUFQX].
- **Administration**: Instill drops as needed for pain and burning/stinging [^1154LUBg].

---

## Clinical evidence supporting recommended dosage

Clinical trials demonstrate that ketorolac 0.4% QID for up to 4 days significantly reduces ocular pain and burning/stinging after PRK compared with vehicle, with **no significant corneal toxicity** reported in these studies [^1154LUBg] [^111jQjKV].

---

## Alternative NSAID regimens

While ketorolac is the **preferred first-line agent**, alternative NSAIDs may be used off-label:

| **Medication** | **Dosage** | **Duration** | **Notes** |
|-|-|-|-|
| Diclofenac sodium 0.1% | 1–2 drops QID | 3 days | Off-label use [^113iJL8b] |
| Bromfenac 0.09% | 1 drop BID | Variable | Off-label use; favorable tolerability profile [^1133k326] |

---

## Safety considerations and monitoring

- **Corneal toxicity**: Rare but serious corneal adverse effects (e.g. keratitis, corneal melt) have been reported with NSAIDs, particularly with prolonged use or in patients with corneal epithelial defects [^114JWEKb].
- **Duration**: Limit NSAID use to the shortest effective course (≤ 4 days) [^114FUFQX].
- **Monitoring**: Patients should be monitored for corneal healing, epithelial defects, and signs of corneal toxicity [^notfound].

---

## Clinical guidelines and expert consensus

The American Academy of Ophthalmology (AAO) recommends topical NSAIDs for postoperative pain control after corneal refractive surgery, with ketorolac 0.4% as a **commonly used agent** [^116XXiiN]. The AAO also emphasizes individualized patient assessment and close monitoring for adverse effects [^116aLqT1].

---

## Summary of recommendations

- **First-line therapy**: Ketorolac tromethamine 0.4% ophthalmic solution, 1 drop QID for up to 4 days [^114FUFQX].
- **Alternative therapy**: Diclofenac sodium 0.1% (1–2 drops QID for 3 days) or bromfenac 0.09% (1 drop BID) may be considered off-label [^113iJL8b] [^1133k326].
- **Monitoring**: Close observation for corneal healing and adverse effects is essential [^116XXiiN].

---

The recommended dosage for ocular pain and inflammation after corneal refractive surgery is **ketorolac tromethamine 0.4% ophthalmic solution, 1 drop in the operated eye 4 times daily for up to 4 days** [^114FUFQX]. This regimen is supported by clinical evidence and aligns with current clinical guidelines.

---

## References

### Ketorolac tromethamine (Acular LS) [^117JeJZt]. FDA (2024). Medium credibility.

The dosage of ketorolac tromethamine OPHTH for treatment of ocular pain and inflammation in adults, after corneal refractive surgery is 1 gtt(s) OPHTH q6-12h for up to 2 weeks following corneal refractive surgery

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^113Pc5Ej]. Clinical Ophthalmology (2019). Medium credibility.

Materials and methods

Patients

These trials included two samples of patients who underwent routine, uncomplicated cataract surgery (eg, phacoemulsification with posterior chamber intraocular lens implantation, not combined with any other surgery), had ≥ grade 2 anterior chamber cells (ie, ≥ 6 cells), and had potential postoperative Snellen distance visual acuity (VA) by pinhole method of at least 20/200 in the study eye. The first trial (hereafter referred to as Trial 1) was conducted at 24 sites (Table S1) within the US between May 2014 and December 2014 and the second trial (hereafter referred to as Trial 2) was conducted at 35 sites (Table S2) within the US between June 2016 and March 2017. Each trial was designed and monitored in accordance with the ethical principles of Good Clinical Practice and the Declaration of Helsinki, and Institutional Review Board approval was obtained by each trial site. Written informed consent was obtained from all subjects at the time of their enrollment and prior to any screening evaluations for the trial.

Individuals of either sex or any race/ethnicity who were ≥ 18 years and were candidates for routine, uncomplicated cataract surgery were eligible for participation in the trials. Patients who required concurrent ocular or non-ocular therapy with any type of medication (eg, nonsteroidal anti-inflammatory drugs, mast cell stabilizers, antihistamines, or decongestants) within 2 days prior to surgery and for the duration of the study were excluded from the trial as were patients with a history of glaucoma, intraocular pressure (IOP) > 21 mmHg at the screening or randomization visit(s), or were being treated for glaucoma in either eye. Also excluded were patients who: 1) had penetrating intraocular surgery in the study eye within 3 months or within 2 weeks in the fellow eye; 2) had selective laser trabeculoplasty within 3 months prior to surgery or had corneal refractive surgery, glaucoma surgery, or corneal transplantation (full thickness, anterior, or posterior) within a year prior to enrollment or were unstable and/or required medication; 3) had active uveitis in either eye or a diagnosis of any type of infection, disease, and/or severe/serious condition that would interfere with study drug effectiveness or study compliance.

---

### Label: KETOROLAC TROMETHAMINE solution / drops… [^114FUFQX]. FDA (DailyMed) (2024). Medium credibility.

Ketorolac tromethamine ophthalmic solution 0. 4%, for topical ophthalmic use Initial U. S. Approval: 1991 INDICATIONS AND USAGE Ketorolac tromethamine ophthalmic solution is a nonsteroidal, anti-inflammatory drug indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. DOSAGE AND ADMINISTRATION One drop of ketorolac tromethamine ophthalmic solution should be applied in the operated eye 4 times per day as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing ketorolac tromethamine 0. 4%. CONTRAINDICATIONS Hypersensitivity to any component of this product. WARNINGS AND PRECAUTIONS. 17 PATIENT COUNSELING INFORMATION
- *
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.

1 Recommended Dosing The recommended dose of ketorolac tromethamine ophthalmic solution is one drop four times a day in the operated eye as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. The most frequent adverse reactions reported with the use of ketorolac tromethamine ophthalmic solutions have been transient stinging and burning on instillation. These reactions were reported by up to 40% of patients participating in clinical trials. Other adverse reactions occurring approximately in 1 to 10% of the time during treatment with other ketorolac tromethamine ophthalmic solutions included allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis, and superficial ocular infections.

14 CLINICAL STUDIES In two double-masked, multi-centered, parallel-group studies, 313 patients who had undergone photorefractive keratectomy received ketorolac tromethamine ophthalmic solution 0. 4% or its vehicle QID for up to 4 days. Significant differences favored ketorolac tromethamine ophthalmic solution for the reduction of ocular pain and burning/stinging following photorefractive keratectomy surgery.

---

### Diclofenac sodium [^113iJL8b]. FDA. Low credibility.

The dosage of diclofenac sodium OPHTH for treatment of ocular pain and photophobia in adults, undefined corneal refractive surgery is 1–2 gtt(s) OPHTH QID for 3 days

---

### Nepafenac [^1166ii8A]. FDA. Low credibility.

The dosage of nepafenac OPHTH for treatment of postoperative ocular inflammation and pain in adults, after ocular surgery is 1 gtt(s) OPHTH daily first 2 weeks of the postoperative period

---

### ACULAR LS-ketorolac tromethamine solution / drops… [^111jQjKV]. FDA (DailyMed) (2024). Medium credibility.

INDICATIONS AND USAGE ACULAR LS ophthalmic solution is a nonsteroidal, anti-inflammatory drug indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. DOSAGE AND ADMINISTRATION One drop of ACULAR LS should be applied in the operated eye 4 times per day as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. 17 PATIENT COUNSELING INFORMATION
- *
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2. 1 Recommended Dosing The recommended dose of ACULAR LS ophthalmic solution is one drop four times a day in the operated eye as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery.
6.

1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse reactions for ACULAR LS ophthalmic solution occurring in approximately 1 to 5% of the overall study population were conjunctival hyperemia, corneal infiltrates, headache, ocular edema, and ocular pain. The most frequent adverse reactions reported with the use of ketorolac tromethamine ophthalmic solutions have been transient stinging and burning on instillation. These reactions were reported by up to 40% of patients participating in clinical trials.

Other adverse reactions occurring approximately in 1 to 10% of the time during treatment with other ketorolac tromethamine ophthalmic solutions included allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis, and superficial ocular infections. 14 CLINICAL STUDIES In two double-masked, multi-centered, parallel-group studies, 313 patients who had undergone photorefractive keratectomy received ACULAR LS 0. 4% or its vehicle QID for up to 4 days. Significant differences favored ACULAR LS for the reduction of ocular pain and burning/stinging following photorefractive keratectomy surgery.

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^1172QdZk]. Clinical Ophthalmology (2019). Medium credibility.

Post-refractive eye surgery

Photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and laser-assisted subepithelial keratectomy (LASEK) are effective surgical procedures used to correct low to moderate myopia and hyperopia. While safe, each technique can induce some degree of ocular pain, inflammation, and/or discomfort. For instance, ablation of the corneal epithelium and associated sensory nerves is a source of postoperative pain in PRK.LASIK uses a microkeratome to raise a corneal flap, which is replaced following laser ablation, but disruption of nerve fibers below the surface in the corneal stroma can cause significant discomfort. LASEK is a modification of LASIK in which the flap is more superficial and does not include anterior stromal tissue, thus maintaining the cornea's biomechanical stability and lowering the risk of flap-related complications, yet patients undergoing this technique can still experience pain or discomfort. Although LASEK would theoretically be expected to cause less postoperative pain than PRK, a meta-analysis of 11 randomized, controlled trials did not find consistent differences between these procedures in pain scores at 1, 2, or 3 days postsurgery. Topical NSAIDs have been used to reduce postoperative pain and inflammation following refractive eye surgeries.–

---

### Diclofenac sodium [^113NZzxh]. FDA. Low credibility.

Labeled indications for Diclofenac sodium (also known as Zorvolex, Voltaren) include:

- Treatment of ocular pain and photophobia in adults, undefined corneal refractive surgery
- Treatment of postoperative ocular inflammation in adults

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^115oHEty]. Clinical Ophthalmology (2019). Medium credibility.

Table 2
Summary of studies

An open-label study in 60 patients (120 eyes) who had undergone LASEK surgery followed by a 7-day course of topical dexamethasone 0.1% four times daily (QID) compared bromfenac 0.1% BID to a tapered regimen of fluorometholone 0.1% (three times daily [TID] for 3 weeks, then BID for 4 weeks, then QD for 4 weeks) administered over the subsequent 11 weeks. The bromfenac group demonstrated improved VA compared to the fluorometholone group at 1 month (P < 0.05) and similar VA at other time points. At 6 months, all bromfenac-treated eyes achieved preoperative best corrected VA, while three eyes in the fluorometholone group failed to achieve preoperative best corrected VA. There were no significant differences between groups in intraocular pressure (IOP) or corneal topography at any time point. Haze was noted in two bromfenac-treated eyes at 1 month and at 2 months, and two fluorometholone-treated eyes at 1 month, but resolved with more frequent NSAID instillation and did not affect VA. Overall, bromfenac was reported to be well tolerated, and no patients discontinued treatment.

Four studies compared bromfenac to ketorolac following refractive eye surgery.–A prospective, randomized study compared bromfenac 0.1% BID (32 patients/eyes) with 0.5% ketorolac QID (32 patients/eyes), each given for 3 days before and 1 day after LASEK surgery. Although the duration of postoperative irritative symptoms (a single outcome assessing symptoms such as pain, photophobia, foreign body sensation, and tearing) was significantly shorter in the bromfenac group (median, 2.0 vs 14.0 days; P = 0.004), there were no significant differences between groups in corneal healing time or VA as measured from day 1 through month 3. A majority (87.5%; 28/32) of patients receiving ketorolac reported eye irritation and burning after administration (eg, pain and burning sensation), while no discomfort was reported in the bromfenac group.

---

### Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery [^116QrGQR]. Journal of Cataract and Refractive Surgery (2019). Medium credibility.

Purpose

To assess the efficacy and safety of a sustained-release intracanalicular dexamethasone insert for the treatment of postoperative ocular inflammation and pain in patients having cataract surgery.

Setting

Twenty-one United States sites.

Design

Prospective multicenter randomized parallel-arm double-masked vehicle-controlled phase 3 study.

Methods

Patients with planned clear corneal cataract surgery were randomized (1:1) to receive dexamethasone insert or placebo, and the treatment was placed in the canaliculus of the eye immediately after surgery (Day 1). The primary efficacy endpoints were complete absence of anterior chamber cells at Day 14 and complete absence of pain at Day 8.

Results

The study comprised 438 adult patients (216 in the treatment arm and 222 in the placebo arm). At Day 14, significantly more patients had an absence of anterior chamber cells in the dexamethasone insert arm compared with placebo (52.3% versus 31.1%; P < .0001). At Day 8, significantly more patients had an absence of ocular pain in the dexamethasone insert arm compared with placebo (79.6% versus 61.3%; P < .0001). The dexamethasone insert arm showed no increase compared with placebo in incidence of all adverse events or ocular adverse events. Twice as many placebo patients required rescue therapy, compared with treated patients at Day 14.

Conclusions

Both primary endpoints were successfully met. In addition, patients receiving the dexamethasone insert experienced a decrease in inflammation after surgery as early as Day 4 through Day 45, and a decrease in pain as early as one day after surgery (Day 2) through Day 45. The dexamethasone insert was well-tolerated, and the adverse events profile was similar to placebo.

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^116KFZm4]. Clinical Ophthalmology (2019). Medium credibility.

Design and treatment

Both studies were randomized, double-masked, parallel-group trials. Randomization was stratified by trial site. In Trial 1, two concentrations and dosing regimens of KPI-121 vs vehicle were administered to one eye for 2 weeks. Subjects were randomized to one of four treatment arms in a 2:2:1:1 ratio: 1) KPI-121 0.25% QID, 2) KPI-121 1% BID, 3) vehicle A QID, 4) vehicle B BID. Following the completion of Trial 1, which demonstrated favorable safety and efficacy profiles for both KPI-121 treatment groups, Trial 2 was initiated to evaluate the safety and efficacy of KPI-121 1% BID compared with vehicle BID administered to one eye for 2 weeks.

As illustrated in Figure 1, subjects in both trials completed up to seven clinic visits (including the surgery day) over 18–33 days of total planned trial duration. Screening occurred between 14 and 1 day(s) prior to surgery, and subjects who met the preoperative screening inclusion/exclusion criteria were allowed to participate in the trial. At Day 0 (surgery), subjects underwent routine, uncomplicated cataract surgery according to normal procedures. Randomization occurred on the day following surgery (Day 1). Subjects who met the qualifying postoperative randomization criteria were eligible for randomization and initiated dosing with study treatment on that day. Subjects self-administered 1–2 drops in the study eye (defined as the surgery eye) for 14 days and recorded dosing information in a daily diary. Following initiation of study treatment dosing, subjects returned to the clinic to be evaluated at Days 4, 8, and 15. The last dose of study treatment was administered on the morning of the Day 15 visit, upon completion of the 14 days of dosing. Following the Day 15 visit, subjects were asked to return to the clinic once between Days 17 and 19 for follow-up and, following completion of all study procedures, were exited from the trial. Efficacy measures were performed on Days 4, 8, and 15. Adverse events (AEs) were assessed across the entire study period.

---

### Difluprednate [^114f8MSm]. FDA. Low credibility.

The dosage of difluprednate OPHTH for treatment of postoperative ocular inflammation and pain in adults, after ocular surgery is 0.05% OPHTH q6-12h

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^115RtJpn]. Clinical Ophthalmology (2019). Medium credibility.

Adapted from Adv Ther, Voolume 27/ Edition 10, Schechter BA, Trattler W, Efficacy and safety of bromfenac for the treatment of corneal ulcer pain, 756–761, Copyright (2010), with permission from Adis, part of Springer Science+Business Media.

Topical administration of NSAIDs is preferred for most ophthalmic indications as it results in high ocular drug concentrations, inclusive of therapeutic levels in posterior ocular tissues, with minimal systemic adverse events (AEs) when compared to systemic administration. Currently, several ophthalmic NSAIDs are indicated for the management of post-cataract surgery pain and inflammation (nepafenac, bromfenac) or post-cataract surgery inflammation (ketorolac, diclofenac).–Other FDA-approved indications include the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery (diclofenac)and the temporary relief of itching due to seasonal allergic conjunctivitis (SAC) (ketorolac). Beyond these approved indications, and due to their ability to inhibit COX activity, other indications have been explored, including prevention and treatment of cystoid macular edema (CME) after cataract or refractive surgery; reduction of pain, discomfort, and inflammation following refractive surgery; treatment of macular edema associated with diabetes and ocular diseases, such as uveitis, branch vein retinal occlusion, and corneal ulcer pain.–Topical NSAIDs may also be beneficial in the treatment of age-related macular degeneration (AMD), which has a complex pathogenesis that includes a major inflammatory component. In addition, the anti-inflammatory properties of these agents may alleviate some of the signs and symptoms of anterior segment and ocular inflammatory surface disorders.–

---

### Clobetasol propionate [^112tPgxY]. FDA (2024). Medium credibility.

The dosage of clobetasol propionate OPHTH for treatment of postoperative ocular inflammation and pain in adults, after ocular surgery is 1 gtt(s) OPHTH BID for 2 weeks (0.05% suspension)

---

### Difluprednate ophthalmic [^113mZcFg]. FDA (2025). Medium credibility.

2 DOSAGE AND ADMINISTRATION

For the treatment of inflammation and pain associated with ocular surgery, instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response. (2.1)
For the treatment of endogenous anterior uveitis, instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated. (2.2)

2.1 Ocular Surgery

Instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response.

2.2 Endogenous Anterior Uveitis

Instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated.

2.3 Prescribing Guidelines

The initial prescription and renewal of the medication order beyond one bottle should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be reevaluated.

Not more than one bottle should be prescribed initially, and the prescription should not be refilled without further evaluation.

---

### Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study [^11282A3W]. Journal of Cataract and Refractive Surgery (2014). Low credibility.

Purpose

To evaluate once-daily nepafenac 0.3% to prevent and treat ocular pain and inflammation after cataract surgery.

Setting

Sixty-five centers in the United States and Europe.

Design

Randomized double-masked vehicle- and active-controlled phase 3 study.

Methods

Patients received nepafenac 0.3% once daily, nepafenac 0.1% 3 times daily, or their respective vehicles from day -1 to day 14 after cataract extraction. An additional drop of study drug was administered 30 to 120 minutes preoperatively. The primary endpoint was the percentage of patients with a cure for inflammation (score of 0 for both aqueous cells and flare) at day 14.

Results

Of randomized patients, 817 received nepafenac 0.3%, 819 received nepafenac 0.1%, and 200 and 206 received the respective vehicles. Significantly more nepafenac 0.3% patients had no inflammation (68.4% versus 34.0%) and were pain free (91.0% versus 49.7%) at day 14 than vehicle patients (both P < .0001). Nepafenac 0.3% was noninferior to nepafenac 0.1% for inflammation (95% confidence interval [CI] -5.73% to 3.17%) and pain-free rates (95% CI, -3.08% to 2.70%). At all postoperative visits, fewer treatment failures (P ≤ .0012) and more clinical successes (P ≤ .0264) were observed with nepafenac 0.3% versus vehicle. Nepafenac 0.3% was well tolerated and had a safety profile comparable to that of nepafenac 0.1%.

Conclusions

Once-daily nepafenac 0.3% was noninferior to nepafenac 0.1% 3 times daily for prevention and treatment of ocular inflammation and pain following cataract surgery. The safety of nepafenac 0.3% was comparable to that of nepafenac 0.1%, with the added convenience of once-daily dosing.

Financial Disclosure

Drs. Modi, Lehmann, Walters, Fong, Christie, Roel, Nethery, and Reiser have been paid consultants to Alcon Research, Ltd. Ms. Sager is an employee of Alcon Research, Ltd. Drs. Tsorbatzoglou, Philipson, and Traverso have no financial or proprietary interest in any material or method mentioned.

---

### Prospective, randomized, fellow eye-controlled study of postoperative pain and inflammation control with an intracanalicular dexamethasone 0.4 mg ophthalmic insert following small incision lenticule extraction [^11578puS]. Clinical Ophthalmology (2022). Medium credibility.

Introduction

Small incision lenticule extraction (SMILE) is a corneal refractive procedure performed with a femtosecond laser in which an intrastromal lenticule is dissected from its anterior and posterior stromal interfaces and removed through a small incision without the need for the creation of a flap. The procedure was approved in the United States in 2016 for the correction of myopia and in 2018 for myopic astigmatism, and has been shown to be effective in correcting hyperopia and presbyopia as well. Meta-analyses suggest SMILE results in less reduction in corneal sensitivity and less incidence of postoperative dry eye compared to femtosecond-laser assisted in situ keratomileusis (FS-LASIK), supporting its preferential use in eyes with pre-existing dryness. The biomechanical strength of the cornea following SMILE is thought to be better preserved compared to FS-LASIK, potentially improving the safety of SMILE in patients with high refractive errors, those who engage in contact sports, or serve in active-duty military.

Following SMILE, the standard postoperative medication regimen includes topical antibiotic and corticosteroid eye drops multiple times per day from multiple bottles with a steroid taper. Recently, there has been a trend for cataract surgeons to move towards a drop-free postoperative experience to improve patient satisfaction and medication compliance following phacoemulsification. A similar shift away from frequent administration of topical therapies following keratorefractive surgery would be expected to improve patients' postoperative experience.

The dexamethasone (DEX) intracanalicular insert (Dextenza, Ocular Therapeutix) is a rod-shaped insert with 0.4 mg of preservative-free dexamethasone embedded within a hydrogel matrix. The DEX insert can be placed into either the superior or inferior punctum and delivers a tapering dose of steroid to the ocular surface for 30 days before dissolving without the need for removal. Phase 3 trials demonstrated the insert's ability to control postoperative pain and inflammation following phacoemulsification cataract surgery with high patient satisfaction.

This study compares postoperative pain, inflammation, and corticosteroid preference in patients undergoing bilateral SMILE treated with the DEX insert in one eye and topical prednisolone acetate in the fellow eye.

---

### 0.2% betamethasone sodium phosphate: a multicenter, randomized, double-masked study to compare its ocular safety, tolerability, and efficacy to vehicle in cataract surgery subjects [^113oRjn9]. Clinical Ophthalmology (2023). Medium credibility.

Methods

This was a phase 2, multicenter, randomized (1:1 ratio), double-masked, vehicle-controlled, parallel-group study undertaken in adult subjects 18 years of age and older who were scheduled to undergo uncomplicated cataract surgery without the aid of a femto (femtosecond) laser. The study consisted of a 16-day dosing phase (Day -1 from surgery through Day 15 postoperatively), followed by a 2‑week evaluation phase (Days 22 and 32). Subjects were provided with a study drug kit per their randomized treatment assignment and given instruction on both dosing at home and on how to complete a dosing and pain assessment diary. Subjects scheduled for cataract surgery were instructed to instill a dose of their assigned treatment BID, preferably 8‑12 hours apart, for 16 days beginning the day before cataract surgery (Day -1), 1 dose administered at least 1 hour prior to cataract surgery (on Day 0) and 1 dose on the evening after cataract surgery, and then 2 doses administered each day for through Day 15; patients were re-evaluated on Days 22 and 32 to ensure no rebound inflammation (included in the safety analysis).

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^113TMM2Y]. Clinical Ophthalmology (2019). Medium credibility.

Primary efficacy endpoints

Anterior chamber cell grade (slit-lamp biomicroscopy)

Ocular inflammation was evaluated by an anterior chamber cell assessment of the study eye performed by the investigator via slit-lamp biomicroscopy. Investigators rated the subjects' anterior chamber cell grade using a 5-point scale (0 = no cells seen; 1 = 1–5 cells; 2 = 6–15 cells; 3 = 16–30 cells; 4 = > 30 cells). Complete resolution of inflammation was defined as an anterior chamber cell grade = 0.

Subject-rated ocular pain assessment

Ocular pain was rated by the subject-rated ocular pain assessment using a 6-point scale (0 = none; 1 = minimal; 2 = mild; 3 = moderate; 4 = moderately severe; 5 = severe). Complete resolution of ocular pain was defined as a grade = 0.

Safety evaluation

Safety assessments included evaluation of AEs, Snellen distance VA by pinhole method, IOP measurement, slit-lamp biomicroscopy (palpebral conjunctival erythema, corneal edema, hyphema, ciliary flush, and bulbar conjunctival injection), dilated ophthalmoscopy, and use of rescue medication.

AEs

An AE was defined as any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-emergent AEs were defined as those events with onset after the first dose of study treatment or, if occurring prior to the first dose, worsened after administration of the first dose. The severity of AEs was classified as mild, moderate, or severe. The relatedness of AEs to the investigational product was also evaluated. Serious AEs were defined as ones resulting in death or that were life threatening, represented a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, resulted in inpatient hospitalization or prolongation of existing hospitalization, a congenital anomaly/birth defect, or the occurrence of a significant medical event.

Snellen distance VA

Snellen distance VA was assessed at all study visits except the surgery visit (Day 0). VA measurement was performed with the Snellen eye chart using the pinhole at a distance of 20 feet (6 m).

IOP measurement

IOP measurements were performed at all study visits except the surgery visit (Day 0) using Goldmann applanation tonometry according to the investigator's standard procedure.

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^1125u8pF]. Clinical Ophthalmology (2019). Medium credibility.

Summary

Topical NSAIDs, while generally approved for management of postsurgical pain and inflammation following cataract surgery, are increasingly being investigated for their utility in other ocular conditions with an inflammatory component. The evidence reviewed here supports the safety and efficacy of bromfenac for a number of indications other than its approved indication (treatment of post-cataract surgery inflammation and pain) or the non-approved but clinically well-established use for prevention of post-cataract surgery CME. Several studies have demonstrated that bromfenac decreases eye pain and irritative symptoms following refractive surgery with no signals for increased rates of side effects or adverse changes in VA or healing/corneal epithelialization.–Bromfenac has shown promise in reducing retinal thickening in patients with DME and has been reported to be beneficial in the management of uveitic macular edema when used in combination with IVTA or IVB including improvements in CMT and VAand reduced frequency of intravitreal injections. Results of several studies suggest that topical bromfenac may be beneficial in patients with anterior segment and/or inflammatory ocular surface disorders, including blepharitis, conjunctivitis/SAC/vernal keratoconjunctivitis, scleritis/episcleritis,–dry eye disease, anterior uveitis, and corneal ulcer pain.

The studies reviewed herein demonstrated that bromfenac was well tolerated when given alone or in combination with intravitreal anti-VEGF agents, topical corticosteroids, or topical mast-cell stabilizers, with the most common AEs being signs of irritation. Corneal complications have been reported with NSAIDs (particularly diclofenac, ketorolac), but were not reported in these reviewed studies. Overall, these findings are consistent with the generally good safety profile of topical ophthalmic NSAIDs.

In conclusion, a growing body of research suggests the potential utility of the topical NSAID bromfenac for various ocular disorders. Additional studies are warranted to further define the potential role of bromfenac ophthalmic solution in clinical practice.

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^116KrdzQ]. Clinical Ophthalmology (2019). Medium credibility.

Primary efficacy endpoints in both trials were evaluated using hierarchical statistical testing using the chi-squared statistic, with the provision that testing would cease if any single hypothesis had a P -value > 0.05. The primary endpoints were tested in the following sequence, comparing KPI-121 1% vs vehicle: 1) the difference in the proportion of study eyes with complete resolution of anterior chamber cells (grade = 0) at postoperative Day 8 maintained through Day 15; 2) the difference in the proportion of study eyes with complete resolution of pain (grade = 0) at postoperative Day 8 maintained through Day 15. Key non-primary endpoints were defined as the difference in the proportions of study eyes with: 1) complete resolution of anterior chamber cells (grade = 0) at postoperative Day 15; 2) complete resolution of ocular pain (grade = 0) at postoperative Day 4; and 3) complete resolution of ocular pain at postoperative Day 15. For each of these primary and key non-primary endpoints, subjects treated with rescue medication prior to Day 15 were considered as nonresponders.

Separate and pooled summaries were created for all safety measures: evaluation of AEs, VA, IOP, slit-lamp biomicroscopy, dilated ophthalmoscopy, and use of rescue medication.

---

### Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery [^117YCVih]. Clinical Ophthalmology (2014). Low credibility.

Conclusion

Place in therapy

Following a comprehensive review of published articles on Lotemax 0.5% suspension, gel, and ointment, our conclusion is as follows. The clinical application of Lotemax ointment offers significant advantage over other currently available steroid medications in the treatment of mild-to-moderate ocular inflammatory conditions. Lotemax ointment should be considered as a first-line therapeutic agent in the treatment of ocular inflammation in adult or pediatric patients following cataract surgery when the patients suffer from comorbid ocular surface disease, chronic ocular allergy, dry eyes, or have a history of steroid response or ocular hypertension. The safety and efficacy of the anti-inflammatory application of this drug has well been established in the literature. Lotemax ointment may also have potential as a first-line anti-inflammatory agent of choice in postoperative settings of strabismus, penetrating glaucoma, and following low-risk PK procedures. Lotemax ointment may also have a significant role where patients have arthritis or a tremor and cannot place drops easily. In clinical settings, where steroid ointment needs to be applied chronically in children or low-vision individuals, utmost care should be taken to avoid the onset of amblyopia and adverse health outcomes. Future double-masked randomized clinical trials will establish the safety and efficacy of Lotemax ointment in the treatment of postoperative inflammation following strabismus, glaucoma, and PK surgeries, and will corroborate our asserted clinical application of this drug.

---

### Loteprednol etabonate [^111558yk]. FDA (2022). Medium credibility.

The dosage of loteprednol etabonate OPHTH for treatment of postoperative ocular inflammation and pain in adults, after ocular surgery is 0.5% OPHTH QID for 2 weeks

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^114EgDQc]. Clinical Ophthalmology (2019). Medium credibility.

An open-label study compared the use of topical bromfenac 0.09% BID (n = 105 eyes) with ketorolac 0.4% QID (n = 107 eyes), each given postoperatively until epithelial healing occurred, for management of pain, discomfort, and photophobia following PRK. Patients undergoing unilateral surgery were randomly assigned to a treatment group; those having surgery on both eyes used one treatment in each eye. Following placement of a BCL on the operated eye, all patients received their assigned NSAID in addition to prednisolone acetate 1% eye drops and gatifloxacin 0.3% ophthalmic solution. No significant differences were noted with regard to postoperative pain, burning, foreign body sensation, photophobia, or epithelial healing rate between the two treatment groups at any time point, with defects fully resolved in both groups at day 5. There were no AEs that were considered related to either treatment.

Bromfenac 0.09% BID and ketorolac 0.5% QID were compared in patients undergoing LASEK (n = 32) or epi-LASEK (n = 8) in a prospective, randomized study. For each patient, the right eye was randomized to either bromfenac or ketorolac, and the left eye was treated with the alternate NSAID. One drop of study medication was instilled in each eye 15 mins prior to surgery and 2 and 4 hrs after surgery, then patients were instructed to instill one drop QID for 4 days. For masking purposes, numbered eye-specific medication vials were provided to patients such that two of the daily bromfenac group instillations were AT. Patient-rated pain scores for the bromfenac-treated eyes were lower as compared to ketorolac-treated eyes on the day of surgery and every day through 4 days postsurgery (P < 0.01 at each time point). Scores for visual blurriness were not statistically different between treatments at any time point. Epithelial healing was complete by day 6 for all eyes. Overall, AEs were similar between treatment groups; eight patients (20%) reported temporary dry eye in both eyes, and two patients (5%) reported temporary irritation in both eyes.

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^116sYTsj]. Clinical Ophthalmology (2019). Medium credibility.

Several studies have evaluated bromfenac for the treatment of ocular discomfort following refractive surgery. In a prospective, double-masked, placebo-controlled case series, 64 patients (120 eyes) were treated with one of four regimens of bromfenac 0.07% and/or artificial tears (AT) to reduce perioperative ocular discomfort related to LASIK surgery (one drop immediately before and after the LASIK procedure): presurgical and postsurgical bromfenac; presurgical bromfenac and postsurgical AT; presurgical AT and postsurgical bromfenac; or presurgical and postsurgical AT (control). Mean postoperative eye pain rating and an averaged all-symptoms rating performed by patients (eye pain, tearing, itching, foreign body sensation, photophobia, discharge, haziness) using the Ocular Comfort Grading Assessment (OCGA) were both lower 1 hr postsurgery in subjects treated with presurgical bromfenac/postsurgical AT (P = 0.02). Among patients who received bromfenac both pre- and postsurgically, an all-symptoms OCGA mean score of zero, indicating no eye pain or other symptoms of discomfort, was reported at the 2-hr postsurgical assessment (P < 0.05 vs control). Ocular discharge and tearing were the symptoms most improved by the bromfenac-containing regimens. Significant reductions in tearing vs control (AT only) were observed with presurgical bromfenac/postsurgical AT (1 and 3 hrs), pre- and postsurgical bromfenac (2 and 5 hrs), and presurgical AT/postsurgical bromfenac (5 hrs). Significant reductions in discharge vs control were observed at all time points through 5 hrs with pre- and postsurgical bromfenac and presurgical bromfenac/postsurgical AT; presurgical AT/postsurgical bromfenac was significantly different from control only at the 2-hr evaluation. Visual acuity (VA) was similar between all treatments at day 1 and 3 months postoperatively. No clinically significant AEs were observed.

---

### Diclofenac sodium (diclofenac) [^1167XJYK]. FDA (2022). Medium credibility.

INDICATIONS AND USAGE

Diclofenac sodium ophthalmic solution, 0.1% is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction and for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery.

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^1169tQPj]. Clinical Ophthalmology (2019). Medium credibility.

Abstract

Topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat postoperative inflammation and pain following cataract surgery and for treatment and prophylaxis of pseudophakic cystoid macular edema (CME). Bromfenac is a brominated NSAID with strong in vitro anti-inflammatory potency. Like other ophthalmic NSAIDs, bromfenac is often used outside of the cataract surgery setting. This paper provides an overview of bromfenac's preclinical ocular pharmacology and pharmacokinetics, followed by a review of 23 published clinical studies in which various marketed bromfenac formulations were used for conditions other than cataract surgery or pseudophakic CME. These include: post-refractive eye surgery; macular edema associated with diabetes, uveitis, or retinal vein occlusion; inflammation associated with age-related macular degeneration; pain related to intravitreal injections; and other ocular anterior segment and surface disorders with an inflammatory component. The published evidence reviewed supports the safety and effectiveness of bromfenac in these additional ophthalmic indications. Bromfenac was well tolerated when given alone or in combination with intravitreal anti-vascular endothelial growth factor agents, topical corticosteroids, or topical mast-cell stabilizers. The most common adverse event reported was ocular irritation. No serious adverse events (ie, corneal epithelial disorders) were reported, although the majority of studies did not systematically evaluate potential side effects. Corneal complications, such as melts reported with diclofenac and ketorolac, were not observed with bromfenac in the studies. In summary, published study data support the clinical utility of bromfenac in various ocular disorders beyond post-cataract surgery. Additional studies are warranted to further define the potential role of bromfenac ophthalmic solution in clinical practice.

---

### A randomized, controlled, prospective study of the effectiveness and safety of an intracanalicular dexamethasone ophthalmic insert (0.4 Mg) for the treatment of post-operative inflammation in patients undergoing refractive lens exchange (RLE) [^111Zmpwu]. Clinical Ophthalmology (2021). Medium credibility.

The intracanalicular insert has been evaluated in three Phase 3 trials for the control of postoperative pain and inflammation following phacoemulsification cataract surgery. Phase 3 trials of the intracanalicular insert versus placebo showed a statistically significant superiority (p < 0.0001) in the absence of anterior chamber cells and lack of ocular pain. The insert was also "well-tolerated" and expressed a similar adverse event profile to the placebo. When compared to the standard drop regime for RLE surgery, the insert will provide patients with fewer post-operative drops, a preservative free medication and punctual occlusion which will increase tear volume and aid in ocular surface rehabilitation. This will improve compliance and proper drug utilization, reduce the toxic effects of multiple drops placed on the surface of the eye and decrease irritation to the surface of the cornea from preservatives. This prospective contralateral ocular study will compare the outcomes of 20 patients undergoing bilateral RLE surgery. In one eye, the patient will receive a topical antibiotic, NSAID and steroid. The contralateral eye will receive a topical antibiotic and NSAID, as well as the dexamethasone ophthalmic insert.

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^1133k326]. Clinical Ophthalmology (2019). Medium credibility.

Topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat postoperative inflammation and pain following cataract surgery and for treatment and prophylaxis of pseudophakic cystoid macular edema (CME). Bromfenac is a brominated NSAID with strong in vitro anti-inflammatory potency. Like other ophthalmic NSAIDs, bromfenac is often used outside of the cataract surgery setting. This paper provides an overview of bromfenac's preclinical ocular pharmacology and pharmacokinetics, followed by a review of 23 published clinical studies in which various marketed bromfenac formulations were used for conditions other than cataract surgery or pseudophakic CME. These include: post-refractive eye surgery; macular edema associated with diabetes, uveitis, or retinal vein occlusion; inflammation associated with age-related macular degeneration; pain related to intravitreal injections; and other ocular anterior segment and surface disorders with an inflammatory component. The published evidence reviewed supports the safety and effectiveness of bromfenac in these additional ophthalmic indications. Bromfenac was well tolerated when given alone or in combination with intravitreal anti-vascular endothelial growth factor agents, topical corticosteroids, or topical mast-cell stabilizers. The most common adverse event reported was ocular irritation. No serious adverse events (ie, corneal epithelial disorders) were reported, although the majority of studies did not systematically evaluate potential side effects. Corneal complications, such as melts reported with diclofenac and ketorolac, were not observed with bromfenac in the studies. In summary, published study data support the clinical utility of bromfenac in various ocular disorders beyond post-cataract surgery. Additional studies are warranted to further define the potential role of bromfenac ophthalmic solution in clinical practice.

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^116K4WHZ]. Clinical Ophthalmology (2019). Medium credibility.

In Trial 2, complete resolution of anterior chamber cells at Day 8 and maintained through Day 15 with no rescue medication prior to Day 15 was demonstrated in 20.7% of subjects in the KPI-121 1% group, compared with 12.4% of subjects in the vehicle BID group (between-group difference for percent responders: 8.3, 95% CI, 2.0–14.7, P = 0.0105). Complete resolution of ocular pain at Day 8 and maintained through Day 15 with no rescue medication prior to Day 15 was demonstrated in 57.1% of subjects in the KPI-121 1% group, compared with 37.1% of subjects in the vehicle BID group (between-group difference for percent responders: 20.0, 95% CI, 11.6–28.4, P < 0.0001). Results for the key non-primary efficacy analysis were also significantly different favoring KPI-121 1% over vehicle BID for each analysis in both trials (Table 2).

Safety

AEs

In both Trial 1 and 2, considered individually and pooled, the incidence of AEs overall, treatment-related AEs, severe AEs, and AEs leading to discontinuation of treatment was lower in the KPI-121 1% BID group than the vehicle BID group (Tables 4 and 5). AEs were reported by 13.7% (53/386) and 17.5% (57/325) of subjects in the KPI-121 1% BID and vehicle BID groups, respectively. Most AEs were of mild or moderate severity. The most commonly reported (≥ 1% in any treatment group) preferred terms were eye pain, headache, photophobia, posterior capsule opacification, corneal edema, and nasopharyngitis (Tables 6 and 7).

VA

In both Trial 1 and Trial 2, a review of Snellen distance VA data revealed no clinically important differences between the KPI-121 1% BID group and the vehicle group in terms of mean changes from baseline in VA at any post-baseline assessment. Pooled summaries illustrated that changes from baseline in VA were negligible in both the KPI-121 1% BID and vehicle groups.

---

### Bromfenac [^1143cmTq]. FDA (2025). Medium credibility.

14 CLINICAL STUDIES

14.1 Ocular Inflammation and Pain

Bromfenac 0.07% QD for the treatment of postoperative inflammation and reduction of ocular pain was evaluated in two multi-center, randomized, double-masked, parallel-group and placebo (vehicle)-controlled studies. Patients undergoing cataract surgery self-administered bromfenac 0.07% or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery. Complete clearance of ocular inflammation (0 cell and no flare) was assessed on Days 1, 3, 8 and 15 post-surgery using slit lamp biomicroscopy. The pain score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular inflammation by Day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07% was superior to vehicle as shown in the following table.

---

### Diclofenac sodium [^115mtnZ6]. FDA. Low credibility.

The dosage of diclofenac sodium OPHTH for treatment of postoperative ocular inflammation in adults is 1 gtt(s) OPHTH QID beginning 24 hours after cataract surgery and continuing throughout the first 2 weeks

---

### Comparing the efficacy of ophthalmic NSAIDs in common indications: a literature review to support cost-effective prescribing [^1116gKq1]. The Annals of Pharmacotherapy (2015). Low credibility.

Objective

To review the commercially available ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs), identify opportunities for therapeutic substitutions within and outside of their Food and Drug Administration (FDA)-approved indications, and identify clinically superior drugs within the class for specific indications.

Data Source

A PubMed search (1992 through January 2014) was performed on the terms diclofenac, ketorolac, flurbiprofen, bromfenac, and nepafenac.

Study Selection and Data Extraction

Clinical trials, meta-analyses, and review articles were evaluated if they were written in English and pertained to human subjects. Studies were excluded if they were in vitro studies, solely evaluated pharmacokinetic or pharmacodynamic properties, did not relate to the topical ophthalmic route, did not evaluate the FDA-approved indications of any available ophthalmic NSAID, or compared a reviewed drug with a nonreviewed drug (without placebo comparison).

Data Synthesis

A total of 67 articles met the criteria for evaluation. Article quality, study design, and dosing of the medications were assessed to determine the clinical applicability of the results. The quality of the article was determined using the Oxford Centre for Evidence-based Medicine Levels of Evidence 1.

Conclusions

Many formulations of the 5 reviewed NSAIDs have been studied across the 4 primary indications. These indications are (1) pain and inflammation associated with cataract surgery, (2) pain associated with corneal refractive surgery, (3) inhibition of intraoperative miosis, and (4) seasonal allergic conjunctivitis. Several studies have directly compared drugs within this class and have identified instances in which certain selections are therapeutically superior or equivalent to another. This information provides practitioners with guidance in selecting an optimal medication.

---

### Bromfenac (bromday) [^114wEfxB]. FDA (2010). Low credibility.

14 CLINICAL STUDIES

14.1 Ocular inflammation and pain following cataract surgery

Clinical efficacy was evaluated in three randomized, double-masked, placebo-controlled trials in which subjects requiring cataract surgery were assigned to Bromday or placebo. Patients were dosed with one drop per eye starting the day before surgery and continuing for 14 days. The primary endpoint was clearing of ocular inflammation by day 15. An additional efficacy endpoint was the number of patients who were pain free on day 1 after cataract surgery.

In 2 of the 3 studies, Bromday ophthalmic solution had statistically significant higher incidence of completely clearing inflammation (46–47% vs. 25–29%) and also had a statistically significant higher incidence of subjects that were pain free at day 1 post cataract surgery (83–89% vs. 51–71%).

---

### Difluprednate ophthalmic emulsion 0.05% (durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery [^113wpAor]. Clinical Ophthalmology (2010). Low credibility.

Objective

To evaluate the efficacy and safety of twice-daily difluprednate ophthalmic emulsion 0.05% (Durezol(®)) versus placebo administered before surgery for managing inflammation and pain following cataract extraction.

Methods

Eligible subjects (N = 121) were randomized 2:1 to topical treatment with 1 drop difluprednate or placebo administered twice daily for 16 days, followed by a 14-day tapering period. Dosing was initiated 24 hours before unilateral ocular surgery. Clinical signs of inflammation (anterior chamber [AC] cell and flare grade, bulbar conjunctival injection, ciliary injection, corneal edema, and chemosis), ocular pain/discomfort, intraocular pressure (IOP), and adverse events were assessed.

Results

Clearing of inflammation on day 14 (primary endpoint), defined as an AC cell grade of 0 (≤ 5 cells) and a flare grade of 0 (complete absence), was achieved in a significantly greater percentage of subjects treated with difluprednate, compared with placebo (74.7% vs 42.5%; P = 0.0006). A significantly greater percentage of difluprednate-treated subjects were free of ocular pain/discomfort on day 14 than placebo-treated subjects (64.6% vs 30.0%; P = 0.0004). Three subjects (3.7%) in the difluprednate group had a clinically significant IOP rise (defined as ≥ 21 mmHg and a change from baseline ≥ 10 mmHg at same visit).

Conclusions

Difluprednate, administered 2 times daily starting 24 hours before cataract surgery, was highly effective for managing ocular inflammation and relieving pain and discomfort postoperatively. Difluprednate was well tolerated and provides a convenient twice-daily option for managing postoperative ocular inflammation.

---

### Bromfenac ophthalmic solution 0.09% [^111ZVdg7]. FDA (2025). Medium credibility.

14 CLINICAL STUDIES

14.1 Ocular Inflammation and Pain Following Cataract Surgery

Clinical efficacy was evaluated in three randomized, double-masked, placebo controlled trials in which subjects requiring cataract surgery were assigned to Bromfenac ophthalmic solution or placebo. Patients were dosed with one drop per eye starting the day before surgery and continuing for 14 days. The primary endpoint was clearing of ocular inflammation by day 15. An additional efficacy endpoint was the number of patients who were pain free on day 1 after cataract surgery.

In 2 of the 3 studies, bromfenac ophthalmic solution had statistically significant higher incidence of completely clearing inflammation (46–47% vs. 25–29%) and also had a statistically significant higher incidence of subjects that were pain free at day 1 post cataract surgery (83–89% vs. 51–71%).

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^116spBqt]. Clinical Ophthalmology (2019). Medium credibility.

Statistical analyses

The primary population for all efficacy analyses was the intent-to-treat (ITT) population, which was defined as all randomized subjects with at least one post-baseline (baseline = Day 1) evaluation. The safety population was defined as all subjects who received at least one dose of the allocated study treatment and from whom at least one safety assessment was obtained after randomization. Imputation for missing data was not applied.

Data from the efficacy and safety evaluations conducted during Trials 1 and 2 were analyzed separately and pooled, given the similarity in study design and purpose. The two vehicle groups in Trial 1 were pooled for all analyses of Trial 1 findings, because preliminary analyses illustrated no statistically significant differences between the two vehicle groups for the primary efficacy endpoints (complete resolution of anterior chamber cells at Day 8 maintained through Day 15 without rescue medication prior to Day 15 [P = 0.3130]; complete resolution of ocular pain at Day 8 maintained through Day 15 without rescue medication prior to Day 15 [P = 0.6320]). Because the purpose of the present research was to evaluate KPI-121 1% BID compared with vehicle, the results from the KPI-121 0.25% QID group from Trial 1 are not summarized here. For pooled efficacy analyses, all vehicle groups (Trial 1 QID, Trial 1 BID, and Trial 2 BID) were pooled; for pooled safety analyses the Trial 1 and Trial 2 BID vehicle groups were pooled but the Trial 1 vehicle QID group was excluded from the analyses.

---

### Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain [^1156HBhr]. Journal of Cataract and Refractive Surgery (2009). Low credibility.

Purpose

To assess the efficacy and safety of difluprednate ophthalmic emulsion 0.05% (Durezol) 2 or 4 times a day compared with those of a placebo in the treatment of inflammation and pain associated with ocular surgery.

Setting

Twenty-six clinics in the United States.

Methods

One day after unilateral ocular surgery, patients who had an anterior chamber cell grade of 2 or higher (> 10 cells) were treated with 1 drop of difluprednate 2 times or 4 times a day or with a placebo (vehicle) 2 times or 4 times a day in the study eye for 14 days. This was followed by a 14-day tapering period and a 7-day safety evaluation. Outcome measures included cleared anterior chamber inflammation (grade 0, ≤ 1 cell), absence of pain, and analysis of ocular adverse events.

Results

Of the 438 patients, 111 received difluprednate 2 times a day, 107 received difluprednate 4 times a day, and 220 received a placebo 2 or 4 times a day. Both difluprednate dosage regimens reduced postoperative ocular inflammation and pain safely and effectively compared with the placebo. A greater proportion of difluprednate-treated patients had a reduction in inflammation and pain at 8 days and 15 days. Three percent of patients in both difluprednate groups had a clinically significant IOP rise (≥ 10 mm Hg and ≥ 21 mm Hg from baseline, respectively) versus 1% in the placebo group.

Conclusions

Difluprednate given 2 or 4 times a day cleared postoperative inflammation and reduced pain rapidly and effectively. There were no serious ocular adverse events. Fewer adverse events were reported in the difluprednate-treated groups than in the placebo group.

---

### Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery [^112jZ6jx]. Clinical Ophthalmology (2014). Low credibility.

Purpose

To review comprehensively the available peer-reviewed published articles in the literature on loteprednol suspension, gel, and ointment in the treatment of ocular inflammation and pain following ocular surgery.

Methods

We conducted a PubMed literature search review of all published articles on keywords associated with loteprednol etabonate and ocular surgery.

Results

A total of 59 peer-reviewed articles were found in the literature. The focus of the majority of the articles was on the safety and efficacy of loteprednol etabonate 0.5% in postoperative control of inflammation and pain following cataract surgery. There were only three articles with a remote association between loteprednol etabonate and keratoplasty.

Conclusion

Lotemax® ointment may also have potential as a first-line anti-inflammatory agent of choice in postoperative settings of strabismus and penetrating glaucoma, and following low-risk penetrating keratoplasty procedures.

---

### Ketorolac tromethamine (Acular LS) [^111uS1HR]. FDA (2024). Medium credibility.

2 DOSAGE AND ADMINISTRATION

One drop of ACULAR LS should be applied in the operated eye 4 times per day as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. (2.1)

2.1 Recommended Dosing

The recommended dose of ACULAR LS ophthalmic solution is one drop four times a day in the operated eye as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery.

2.2 Use With Other Topical Ophthalmic Medications

ACULAR LS has been safely administered in conjunction with other topical ophthalmic medications such as alpha-agonists, antibiotics, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^112pohMk]. Clinical Ophthalmology (2019). Medium credibility.

Introduction

Intraocular inflammation is an anticipated sequela of intraocular surgery, such as cataract removal and intraocular lens implantation, and is manifested principally as conjunctival injection, corneal edema, ciliary flush, and aqueous cells and flare. In general, trauma to the internal structures of the eye is accompanied by the production of prostaglandins and other vasoactive moieties, an increase in blood flow to the affected area, and extravasation of protein and cellular blood elements. Untreated inflammation may lead to complications such as cystoid macular edema and corneal scarring. Thus, managing and treating postoperative inflammation is an important goal following cataract surgery.

Current postoperative medication regimens commonly include topical corticosteroids. Treatment with corticosteroids is employed to reduce pain and discomfort, and to facilitate recovery of the blood–aqueous barrier. When administered at the time of surgery and during the immediate postoperative period, corticosteroids can reverse the clinical manifestations of inflammation. In the US, topical corticosteroids are routinely prescribed with four times daily (QID) dosing for at least 2 weeks following cataract surgery.

KPI-121 1% (INVELTYS™) was developed by Kala Pharmaceuticals, Inc. (Waltham, MA, USA) and recently approved by the US Food and Drug Administration (FDA) for the treatment of postoperative inflammation and pain following ocular surgery.KPI-121 1% contains loteprednol etabonate (LE) 1% formulated using a proprietary technology known as mucus penetrating particles (MPP). MPP utilizes nanoparticles of drug formulated to enhance penetration of loteprednol through the mucus layer of the tear film, resulting in increased penetration into ocular tissues.

LE was chosen because it is an ester corticosteroid and is rapidly absorbed into ocular issues. After exerting its effects, loteprednol is rapidly metabolized to inactive metabolites and has been reported to have fewer side effects than traditional glucocorticoids. Preclinical studies have shown that loteprednol formulated with MPP technology achieved higher ocular exposure than Lotemax ® ophthalmic suspension 0.5% (Bausch + Lomb, Rochester, NY, USA), with peak concentrations approximately three-fold higher in ocular tissues and aqueous humor. The profile of KPI-121 has the potential to deliver potent anti-inflammatory activity with less frequent dosing, while still retaining the safety profile of loteprednol.

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^112yA9Ds]. Clinical Ophthalmology (2019). Medium credibility.

Efficacy

Statistically significant between-group differences were observed for both primary efficacy endpoints, in both Trials (Table 2).

Pooled analyses of the two trials also demonstrated statistically significant results favoring KPI-121 1% over vehicle for each primary and key non-primary endpoint, as summarized in Table 3. Results for these endpoints are presented graphically in Figure 2 (for responders on anterior chamber cells at Days 8 and 15) and Figure 3 (for responders on ocular pain at Days 4, 8, and 15).

In Trial 1, complete resolution of anterior chamber cells at Day 8 and maintained through Day 15 with no rescue medication prior to Day 15 was demonstrated in 31.2% of subjects in the KPI-121 1% BID group, compared with 15.1% of subjects in the pooled vehicle group (between-group difference for percent responders: 16.1, 95% CI, 5.9–26.4, P = 0.0024). Complete resolution of ocular pain at Day 8 and maintained through Day 15 with no rescue medication prior to Day 15 was demonstrated in 53.6% of subjects in the KPI-121 1% BID group, compared with 34.1% of subjects in the pooled vehicle group (between-group difference for percent responders: 19.5, 95% CI, 7.4–31.5, P = 0.0019). Results for the key non-primary efficacy analysis were also significantly different favoring KPI-121 1% over vehicle for each analysis.

---

### A randomized, controlled, prospective study of the effectiveness and safety of an intracanalicular dexamethasone ophthalmic insert (0.4 Mg) for the treatment of post-operative inflammation in patients undergoing refractive lens exchange (RLE) [^113U5eXj]. Clinical Ophthalmology (2021). Medium credibility.

Introduction

Refractive Lens Exchange (RLE) is a well-studied and common refractive surgery option for patients seeking to improve their vision. RLE offers patients a method for eliminating their refractive error by surgically removing their intraocular lens and replacing it with an appropriate implant lens. It is commonly used when patients do not meet the requirements for other forms of refractive surgery or desired presbyopic correction. The key factors in post-operative evaluation are monitoring the tear film and subsequent corneal staining, evaluating the anterior chamber (AC) for ocular inflammation, ensuring the intraocular pressure (IOP) is within standard ranges, determining if the posterior chamber intraocular lens is centered and properly positioned and evaluating the vitreous and retina for significant signs of inflammation or cystoid macular edema (CME). It is also important to monitor and prevent infection within the eye, better known as endophthalmitis. Post-operatively patients are treated with antibiotic therapy to prevent infection, steroid drops to reduce inflammation and non-steroidal anti-inflammatory drugs (NSAIDs) for pain management and retinal inflammation.

The use of drops post-RLE is considered by most to be standard of care, but the treatment regimens vary depending on the surgeon and practice preference. Difficulties with post-operative drop treatments are frequently encountered from both the patient and physician's perspective. The intracanalicular insert may reduce the challenges often seen with physician offices for obtaining prior authorization for ophthalmic drops. Patients routinely struggle with drop installation, timing, and compliance. With RLE, it is critical to the visual outcome, overall health, and safety of the eye for this post-operative regime to be both convenient and effective.

The intracanalicular insert is a recently approved, sustained release form of dexamethasone. The insert is a polyethylene glycol hydrogel rod containing 0.4 mg of the preservative free steroid dexamethasone and is used for the treatment of pain and post-operative inflammation in patients who have undergone RLE and other forms of ocular surgery. The intracanalicular insert is placed into the canaliculus through the punctum, swells upon hydration and anchors into place. As it dissolves, it provides a sustained and tapered release of dexamethasone for up to 30 days without the need for post-treatment removal. Due to the presence of fluorescein, the implant is easily visualized with a cobalt blue light and can be placed during the pre-operative period, during the procedure or at a post-operative appointment.

---

### Ketorolac tromethamine (Acular LS) [^114TRnpv]. FDA (2024). Medium credibility.

Labeled indications for Ketorolac tromethamine (also known as Acunivive, Toronova SUIK, Sprix, Acular, Toradol) include:

- Treatment of ocular pain and inflammation in adults, after corneal refractive surgery

---

### Refractive surgery preferred practice pattern ® [^116aLqT1]. Ophthalmology (2023). High credibility.

Postoperative management — The operating ophthalmologist has the ultimate responsibility for the preoperative assessment and postoperative care of the patient and has an ethical obligation to the patient that continues until postoperative rehabilitation is complete. The operating ophthalmologist should also provide those aspects of postoperative care that are within the unique competence of the ophthalmologist, and if such follow-up care is not possible, the operating ophthalmologist must make arrangements before surgery for the patient to obtain another ophthalmologist for postoperative care with the prior approval of the patient and the ophthalmologist; transfer of care takes place when there is transfer of responsibility for a patient's care from one qualified health care provider functioning within his or her scope of practice to another who also functions within his or her scope of practice. The ophthalmologist who performs surgery has an obligation to inform patients about medication instructions, activity restrictions, postoperative eye protection, required visits, signs and symptoms of possible complications, and information for accessing emergency care, and should inform patients of their responsibility to follow advice and to notify the ophthalmologist promptly if problems occur; patients should always have access to an ophthalmologist for appropriate care if serious problems arise. Postoperative medication regimens vary among practitioners, and topical corticosteroids and NSAIDs are also used for control of postoperative inflammation, but there is insufficient high-level evidence to compare these interventions (++, Moderate, Discretionary), making it the decision of the operating surgeon to use one or both of these medication classes.

---

### A randomized fellow-eye clinical trial to evaluate patient preference for dexamethasone intracanalicular insert or topical prednisolone acetate for control of postoperative symptoms following bilateral femtosecond laser in site keratomileusis (LASIK) [^117CBFML]. Clinical Ophthalmology (2020). Medium credibility.

Introduction

Corneal inflammation can occur after laser-assisted in situ keratomileusis (LASIK) and other corneal refractive procedures.–Although clinically evident corneal inflammation is uncommon after LASIK, subclinical inflammation is present involving activation of corneal keratocytes and release of cytokines.–Consequences of postoperative inflammation in the post-LASIK eye can range from mild and transient irritation to chronic postoperative dry eye to the more devastating diffuse lamellar keratitis, which must be differentiated from pressure-related LASIK interface complications such as pressure-induced stromal keratitis or post-LASIK edema-induced keratopathy.-

Anti-inflammatory prophylaxis is a standard component of perioperative care in eyes undergoing corneal refractive surgery. This can take many forms, from single-agent corticosteroids to fixed combinations of steroids and antibiotics for antimicrobial prophylaxis. No widespread standard has been described.

The US Food and Drug Administration recently approved a novel sustained-release form of dexamethasone (Dextenza, Ocular Therapeutix, Bedford, MA). This small insert, intended for intracanalicular placement, is a polyethylene glycol hydrogel rod impregnated with 0.4 mg of preservative-free dexamethasone. It is inserted through the punctum into the canaliculus, swells upon hydration, and anchors into place, dissolving over time to deliver a sustained and tapered dose of dexamethasone for up to 30 days without the need for post-treatment removal. It can be inserted preoperatively, intraoperatively, or postoperatively at surgeons' discretion. The hydrogel is conjugated with fluorescein for enhanced visualization during examination.

The dexamethasone insert is indicated for the control of pain and inflammation following ocular surgery. It has been evaluated in three Phase 3 trials for the control of postoperative pain and inflammation following phacoemulsification cataract surgery. Patients from these studies reported favorable satisfaction, convenience, and comfort with the insert. To our knowledge, there are no published reports of its use in controlling postoperative symptoms and ocular surface signs following corneal refractive surgery. In addition to control of symptoms and ocular surface signs arising from the dexamethasone active ingredient, patients undergoing corneal refractive surgery may benefit from the ocular surface effects of punctal occlusion. In this paper, we report the results of a prospective, randomized trial to evaluate patients' experience and preference for the dexamethasone insert or topical prednisolone acetate for the control of postoperative pain and inflammation following LASIK.

---

### Safety and efficacy of bromfenac ophthalmic solution (bromday) dosed once daily for postoperative ocular inflammation and pain [^111ECKd9]. Ophthalmology (2011). Low credibility.

Purpose

To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution (bromfenac) 0.09% dosed once daily for the treatment of ocular inflammation and pain after cataract surgery with posterior chamber intraocular lens implantation.

Design

Randomized, double-masked, vehicle-controlled or active-controlled, multicenter, clinical trials.

Participants and Controls

A total of 872 subjects (872 study eyes: bromfenac in 584, placebo in 288).

Methods

Four randomized, double-masked, vehicle or active-controlled, clinical trials were conducted at 134 ophthalmology clinics in the United States. Subjects aged ≥ 18 years were randomized to receive either bromfenac 0.09% or placebo dosed once daily beginning 1 day before cataract surgery (day -1), continuing on the day of surgery (day 0), and continuing for an additional postoperative 14 days. Subjects were evaluated for efficacy and safety on days 1, 3, 8, 15, and 22. The primary efficacy end point was cleared ocular inflammation, measured by the summed ocular inflammation score (SOIS; anterior chamber cells and flare) by day 15. The secondary efficacy end point was the number of subjects who were pain-free at day 1. The data from the 4 trials were pooled for analyses.

Main Outcome Measures

The SOIS and ocular pain.

Results

The proportion of subjects who had cleared ocular inflammation by day 15 was significantly higher in the bromfenac 0.09% group than in the placebo group (P < 0.0001). The mean SOIS in the bromfenac 0.09% group was significantly lower than in the placebo group at days 3, 8, 15, and 22 (P < 0.0001). The proportion of subjects who were pain-free at days 1, 3, 8, and 15 was significantly higher in the bromfenac 0.09% group than in the placebo group (P < 0.0001). The incidence of adverse events reported in the bromfenac 0.09% group was significantly lower than in the placebo group (P < 0.0001). On day 15, 84.0% of the bromfenac subjects had ≥ 1-line improvement in visual acuity compared with 66.1% of placebo subjects (P < 0.0001).

Conclusions

Bromfenac 0.09% dosed once daily was clinically safe and effective for reducing and treating ocular inflammation and pain associated with cataract surgery.

Financial Disclosure(S)

Proprietary or commercial disclosure may be found after the references.

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^111hLFdW]. Clinical Ophthalmology (2019). Medium credibility.

Purpose

KPI-121 is a nanoparticle suspension of loteprednol etabonate with improved ocular pharmacokinetics compared with marketed formulations. The efficacy and safety of KPI-121 1% ophthalmic suspension (INVELTYS™) dosed twice daily (BID) were evaluated in participants who had undergone cataract surgery.

Materials and Methods

In two multicenter, randomized, double-masked, parallel-group, vehicle-controlled clinical trials, 386 participants with ≥ grade 2 anterior chamber cells (≥ 6 cells) on the day following routine cataract surgery were treated with KPI-121 1% and 325 participants were treated with placebo (vehicle); each group was dosed BID for 2 weeks. Primary efficacy endpoints were complete resolution of ocular inflammation by slit-lamp biomicroscopy and complete resolution of subject-rated ocular pain at Days 8 and 15 with no rescue medication before Day 15. Safety assessments included adverse events (AEs), visual acuity, intraocular pressure measurements, and evaluation of ocular AEs by slit-lamp biomicroscopy and dilated ophthalmoscopy.

Results

Both trials achieved statistical significance favoring KPI-121 1% BID for both primary efficacy endpoints. Combined data analysis showed that significantly more participants treated with KPI-121 vs vehicle achieved complete resolution of anterior chamber cells at Days 8 and 15 (P ≤ 0.0001) and complete clearing of ocular pain at Days 4, 8, and 15 (P < 0.0001). AEs were reported more frequently with vehicle than KPI-121.

Conclusion

KPI-121 1% ophthalmic suspension was effective in resolving postoperative ocular inflammation and pain when dosed BID for 2 weeks in patients following cataract surgery. KPI-121 was found to be safe and well tolerated in both trials.

---

### Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery [^111F7Yv4]. Clinical Ophthalmology (2011). Low credibility.

Background

The purpose of this review was to provide a critical appraisal of the literature supporting the efficacy of ophthalmic ketorolac (Acuvail(®)) in the treatment of pain and inflammation after cataract surgery.

Methods

Literature search and expert opinion of the authors.

Results

Recent studies indicate greater intraocular drug levels in the anterior chamber and iris-ciliary body after topical application of Acuvail in comparison with older formulations of ketorolac. A large randomized, multicenter, placebo-controlled study demonstrated significantly less inflammation and pain after cataract surgery using Acuvail.

Conclusion

Acuvail appears to be effective in reducing post-cataract surgery pain and inflammation.

---

### Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery [^111YQ9ak]. Clinical Ophthalmology (2019). Medium credibility.

Results

Patient disposition and demographics

Across the two trials, 900 subjects were enrolled and included in the ITT populations: 380 subjects in Trial 1 and 520 subjects in Trial 2. Of these 900 subjects, 386 subjects were treated with KPI-121 1% BID, 125 subjects were treated with KPI-121 0.25% QID, 325 subjects were treated with vehicle BID, and 60 subjects were treated with vehicle QID. As illustrated in Table 1, there were no significant differences in the demographics of the enrolled populations between the two trials, and there were no significant differences among the treatment groups within each trial. Mean (range) ages were 67.7 (38–89) years for the pooled KPI-121 1% BID group (N = 386) and 69.4 (40–90) years for the pooled vehicle group (N = 385). Both trials, considered individually as well as pooled, enrolled more females than males, with a majority of subjects being White and not Hispanic/Latino.

---

### Loteprednol etabonate [^114eRtQh]. FDA (2022). Medium credibility.

Labeled indications for Loteprednol include:

- Treatment of postoperative ocular inflammation and pain in adults, after ocular surgery

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^113trUay]. Clinical Ophthalmology (2019). Medium credibility.

In a prospective, double-masked study, 29 patients (58 eyes) undergoing PRK were randomized to treatment with nepafenac 0.1% (n = 15 patients/30 eyes), bromfenac 0.09% (n = 6 patients/12 eyes), or ketorolac 0.4% (n = 8 patients/16 eyes); each topical NSAID was administered TID beginning 1 day preoperatively and continuing for 1 week postoperatively. By day 3, all groups showed a significant reduction in pain score compared to before NSAID use (P < 0.05). Time to reepithelialization (complete closure) occurred significantly sooner with nepafenac (mean ± SD, 5.5 ± 1.59 days) and ketorolac (5.6 ± 1.23 days) compared to bromfenac (7.3 ± 2.53 days; P < 0.05). Time to healing in this study was longer than reported in a previous study comparing nepafenac and ketorolac. The authors suggested that this could have been a consequence of their study procedures, which included removing the bandage contact lens (BCL) and application of a drop of fluorescein sodium ophthalmic solution 1% at each postoperative visit. Physical manipulation of the BCL and application of fluorescein, which is known to be toxic to epithelial cells, may have delayed reepithelialization. Moreover, the concurrent use of different antibiotics (moxifloxacin 0.5% in nepafenac eyes and gatifloxacin 0.3% in all other eyes) along with differences in sample size may have confounded study results further. Nevertheless, there were no AEs reported and no evidence of corneal toxicity in any treatment group.

---

### Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery [^116JcKy9]. Clinical Ophthalmology (2014). Low credibility.

For studies published on Lotemax gel or suspension, we found a multicenter investigator-masked randomized trial by Lane and Holland showing the LE 0.5% (Lotemax) suspension to be equivalent to prednisolone acetate 1.0% (Pred Forte) in control of inflammation following cataract surgery. The efficacy of LE was examined in 88 patients with a 3-week follow-up; there was less IOP fluctuation on days 1 and 3. Statistical significance was not published. Both LE and prednisolone acetate medications were well tolerated by patients. In the pivotal FDA trials looking at postoperative patients in a randomized, double-masked, vehicle-controlled evaluation of the efficacy and safety of LE after cataract surgery, the resolution of anterior chamber inflammation was observed in 55% of 203 patients in the LE group and in 28% of the vehicle group (P < 0.001) after 14 days. No adverse outcome was observed in either group, and no IOP elevation was noted in the LE group. In another randomized study by Stewart et al to evaluate the efficacy and safety of LE drops in controlling ocular inflammation, effective resolution of anterior chamber inflammation was found in 64% of patients in the LE group and in 29% of patients in the control (vehicle) group. In evaluating the efficacy of LE in the management of pain following cataract surgery, Comstock and Usner showed 84% control of pain for the LE group and 56% for the placebo group (P < 0.005). In controlling discomfort, their study showed 79% efficacy for the LE group and 42% for the placebo group. In a prospective randomized study to evaluate the efficacy of LE gel 0.5% in controlling pain and inflammation, Fong et al showed 31.1% of LE-treated patients and 13.9% of vehicle-treated patients had complete resolution of anterior chamber cells at 8 days. There were 407 patients in the study. No adverse reactions to medications were noted. Furthermore, the authors showed 75.7% of LE-treated patients and 45.8% of vehicle-treated patients had no pain (grade 0). In comparative studies evaluating LE suspension 0.5%, other corticosteroids, or NSAIDs, Stewart found no statistically significant difference in efficacy between the LE- and fluorometholone acetate 0.1%-treated groups. This was a randomized double-masked study of 30 postoperative cataract patients looking at the resolution of the anterior segment inflammation. No adverse outcome was observed in either group. In another randomized comparative study, Oner et al looked at the efficacy of LE 0.5% suspension versus FML 0.1% versus prednisolone acetate 1% (PF 1%) in the treatment of vernal keratoconjunctivitis. The authors showed no statistically significant differences in outcome measures between the LE and PF groups for the 57 enrolled patients. The FML-treated group showed less improvement than the LE and PF groups. The study also showed statistically significant IOP elevation after the third day of treatment with PF. The authors concluded LE was as effective as PF and more effective than FML in treatment of vernal keratoconjunctivitis without side effects. Holzer et al published a prospective randomized comparative study of LE suspension 0.5% and ketorolac tromethamine ophthalmic solution 0.5% for treatment of inflammation after cataract surgery, and showed no statistically significant difference in any final outcome parameters between the two groups up to 30 days postoperatively. Postoperative pain was not assessed. The authors noted no adverse side effects in either group. A more recent multicenter, randomized, double-masked study by Rajpal et al evaluated the efficacy of LE gel 0.5% compared to vehicle for resolving inflammation and pain following cataract surgery. The authors showed LE gel had superior efficacy in reducing anterior chamber cells and flare in patients following cataract surgery in comparison to the vehicle. The authors concluded that LE gel 0.5% would likely be more suitable in treatment of ocular inflammation following ocular surgery. Because of formulation improvements, including no preservatives and a more physiological pH, the authors felt it may provide added benefit to patients. We were unable to identify any publications supporting Lotemax (in any form) as the preferred choice of ocular inflammation following PK surgeries. The Randleman and Stulting survey showed that of the 396 corneal transplant surgeons participating, 37%–90% used topical prednisolone as their primary or preferred routine anti-inflammatory drug of choice following PK. Also, 81%–91% used topical prednisolone acetate 1% (PF) for various manifestations of graft rejection at all time points. Lotemax suspension was used in 12%–26% of cases. That study, as well as others, concluded that topical prednisolone remained the mainstay for the prevention and treatment of corneal graft rejection; however, they pointed out that the role of LE seems to have been expanding. In a more recent retrospective study of 30 patients by Holland et al to evaluate for a clinical reduction in IOP in known steroid responders using LE 0.5% ophthalmic suspension as second-line rescue therapy after corneal transplantation, the authors concluded that switching to LE from PF was successful in reducing IOP. Reduction of IOP was noted in all 30 patients who were switched from PF to LE. The authors concluded that switching to LE from PF was successful in reducing IOP. The study showed no increase in the rate of allograft rejection. Additionally, they recommended that physicians consider LE 0.5% in the prophylaxis of allograft rejection in steroid responders, due to its lower potential for causing elevated IOP. In a prospective randomized multi-centered double-masked trial, Rajpal et al compared LE gel 0.5% to a vehicle and showed LE gel 0.5% to be efficacious and safe in treating postoperative inflammation and pain. The study included 203 patients followed for 18 days after cataract surgery. A total of four treatment-emergent serious adverse events were noted during the study; none was felt related to the study drug. In both treatment groups, the mean IOP remained stable, and no cases of steroid response were observed. Finally, in a large randomized, double-masked, parallel-group, vehicle-controlled study of LE, Comstock et al published data on 805 patients assessed for safety and efficacy of LE ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. The study showed LE ointment to be both efficacious and well tolerated in the treatment of ocular inflammation and pain following cataract surgery. Mean IOP for all study eyes in both treatment arms (LE and prednisolone) was consistently lower than baseline at all posttreatment visits. This is not surprising, as many studies have shown decreased IOP after cataract surgery. One patient in the LE ointment-treated group experienced cystoid macular edema, requiring the patient to exit from the study. The authors, in their conclusion, asserted that the integrated results of all published studies on LE ointment show the medication to be effective and well tolerated in the treatment of postoperative inflammation and pain following ocular surgery. Tables 1 and 2 summarize the available published literature on efficacy of Lotemax and intraocular inflammation.

---

### Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies [^111uEUf8]. Clinical Ophthalmology (2019). Medium credibility.

Bromfenac has also been evaluated for the treatment of corneal ulcer pain in a prospective, non-randomized trial. Eyes with bacterial or fungal infiltrates were treated either with bromfenac 0.9% BID (n = 25 eyes) plus standard anti-infective agents or with standard anti-infective agents alone (controls; n = 10 eyes). Although the primary endpoint of time to healing did not differ significantly between treatment groups, significantly more eyes treated with bromfenac had no pain by day 3 compared with control eyes (52% vs 0%, P = 0.023). The epithelium of bromfenac-treated eyes was also more likely to have healed by day 20 (68% vs 10% of control eyes, P = 0.040). Additionally, bromfenac was associated with significant functional improvement, reflected by a shorter mean time to return to regular daily activities (3.2 days vs 25.8 days in controls, P < 0.001) and a higher percentage of patients returning to normal activities within 2 days of starting treatment (71% vs 0% of controls, P = 0.018). Bromfenac treatment was not associated with any corneal AEs, although larger studies are needed to establish the safety of bromfenac in this patient population. It should also be noted that NSAIDs may cause sterile corneal ulcers with continued use, especially in at-risk patients.

Results of these studies suggest that bromfenac may have benefits across a range of anterior segment and ocular surface disorders. In all studies, bromfenac was well tolerated with no clinically important side effects reported. It should be noted that use of bromfenac and other topical NSAIDs has been associated with adverse corneal sequelae such as corneal erosions, ulceration, and perforation, particularly in patients considered high risk (complicated oral surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases, rheumatoid arthritis, repeat ocular surgeries within a short time) and those treated with prolonged use after (> 14 days) or before (> 24 hrs) surgery.

---

### Bromfenac sodium (bromfenac ophthalmic solution) [^111abkhn]. FDA (2025). Medium credibility.

14 CLINICAL STUDIES

14.1 Ocular Inflammation and Pain

Bromfenac 0.07% QD for the treatment of postoperative inflammation and reduction of ocular pain was evaluated in two multi-center, randomized, double-masked, parallel-group, and placebo (vehicle)-controlled studies. Patients undergoing cataract surgery self-administered bromfenac 0.07% or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery. Complete clearance of ocular inflammation (0 cell and no flare) was assessed on Days 1, 3, 8, and 15 postsurgery using slit lamp biomicroscopy. The pain score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular inflammation by Day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07% was superior to vehicle as shown in the following table.

---

### ACULAR LS-ketorolac tromethamine solution / drops… [^1154LUBg]. FDA (DailyMed) (2024). Medium credibility.

INDICATIONS AND USAGE ACULAR LS ophthalmic solution is a nonsteroidal, anti-inflammatory drug indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. DOSAGE AND ADMINISTRATION One drop of ACULAR LS should be applied in the operated eye 4 times per day as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing ketorolac tromethamine 0. 4%. CONTRAINDICATIONS Hypersensitivity to any component of this product. WARNINGS AND PRECAUTIONS. 17 PATIENT COUNSELING INFORMATION
- *
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.

1 Recommended Dosing The recommended dose of ACULAR LS ophthalmic solution is one drop four times a day in the operated eye as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. The most frequent adverse reactions reported with the use of ketorolac tromethamine ophthalmic solutions have been transient stinging and burning on instillation. These reactions were reported by up to 40% of patients participating in clinical trials. Other adverse reactions occurring approximately in 1 to 10% of the time during treatment with other ketorolac tromethamine ophthalmic solutions included allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis, and superficial ocular infections. Other adverse reactions reported rarely with the use of ketorolac tromethamine ophthalmic solutions included: corneal ulcer, eye dryness, and visual disturbance.

14 CLINICAL STUDIES In two double-masked, multi-centered, parallel-group studies, 313 patients who had undergone photorefractive keratectomy received ACULAR LS 0. 4% or its vehicle QID for up to 4 days. Significant differences favored ACULAR LS for the reduction of ocular pain and burning/stinging following photorefractive keratectomy surgery.

---

### Dexamethasone 0.4mg sustained-release intracanalicular insert in the management of ocular inflammation and pain following ophthalmic surgery: design, development and place in therapy [^113UFXp6]. Clinical Ophthalmology (2020). Medium credibility.

Inflammation and pain are two prevalent findings after ocular surgery. Corticosteroids are widely administrated as a core treatment to control post-surgical inflammation and pain. Improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, and the negative impact of preservatives used in many of these eye drops, has made a strong case for novel therapies in the treatment of post-operative pain and inflammation. This review of the literature will focus on the role of intracanalicular sustained-release dexamethasone (Dextenza, Ocular Therapeutix, Bedford, MA, USA) for the management of ocular inflammation and pain.

---

### A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery [^116n3edz]. Clinical Ophthalmology (2007). Low credibility.

The non-steroidal anti-inflammatory drug (NSAID) ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation containing 20% less active ingredient that the original formulation, is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Clinical studies have shown ketorolac tromethamine 0.4% to be as effective as ketorolac tromethamine 0.5% to control inflammation after cataract surgery including prevention of cystoid macular edema (CME). Its efficacy to inhibit miosis during cataract surgery as well as its role in the treatment of dry eye has been reported. The purpose of this paper is to review the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery.

---

### Evaluating a sustained-release dexamethasone insert as adjunctive therapy for inflammation and pain post-corneal transplantation [^114LAznX]. Clinical Ophthalmology (2024). Medium credibility.

Sample Size

The sample size in this study was determined by the number of eligible participants available during the study period. We did not perform power calculations to predetermine the sample size due to these constraints.

---

### Bromfenac sodium (bromfenac ophthalmic solution, 0.07%) [^115sS28K]. FDA (2025). Medium credibility.

14 CLINICAL STUDIES

14.1 Ocular Inflammation and Pain

Bromfenac 0.07% QD for the treatment of postoperative inflammation and reduction of ocular pain was evaluated in two multi-center, randomized, double-masked, parallel-group, and placebo (vehicle)-controlled studies. Patients undergoing cataract surgery self-administered bromfenac 0.07% or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery. Complete clearance of ocular inflammation (0 cell and no flare) was assessed on Days 1, 3, 8, and 15 postsurgery using slit lamp biomicroscopy. The pain score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular inflammation by Day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07% was superior to vehicle as shown in the following table.

---

### A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery [^112vQPmp]. Clinical Ophthalmology (2015). Low credibility.

Background

While loteprednol etabonate ophthalmic gel 0.5% (LE gel) is approved for treatment of postoperative ocular inflammation and pain, there have been no reported studies in patients undergoing laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK).

Methods

This was a retrospective chart review conducted at five refractive surgical centers in the USA. Data were collected from primary LASIK or PRK surgery cases in which LE gel was used postoperatively as the clinician's routine standard of care and in which patients were followed-up for up to 6 months. Data extracted from charts included patient demographics, surgical details, LE gel dosing regimen, pre- and postsurgical refractive characteristics, intraocular pressure (IOP) measurements, and visual acuity. Primary outcomes included postoperative IOP elevations, adverse events, and early discontinuations.

Results

Data were collected on 189 LASIK eyes (96 patients) and 209 PRK eyes (108 patients). Mean (standard deviation [SD]) years of age at surgery was 36.0 (11.7) and 33.9 (11.3) in LASIK and PRK patients. LE gel was prescribed most often four times daily during the first postoperative week, regardless of procedure; the most common treatment duration was 7–14 days in LASIK and ≥ 30 days in PRK patients. No unusual corneal findings or healing abnormalities were reported. Mean postoperative uncorrected distance visual acuity was 20/24 in LASIK and 20/30 in PRK eyes. Mild/trace corneal haze was reported in 20% of PRK patients; two PRK patients with moderate/severe corneal haze were switched to another corticosteroid. Mean postoperative IOP did not increase over time in either LASIK or PRK eyes (P ≥ 0.331); clinically significant elevations from baseline in IOP (≥ 10 mmHg) were noted in only three eyes of two PRK patients.

Conclusion

LE gel appears to have a high level of safety and tolerability when used for the management of postoperative pain and inflammation following LASIK and PRK surgery.

---

### Difluprednate 0.05% versus prednisolone acetate post-phacoemulsification for inflammation and pain: an efficacy and safety clinical trial [^113pzQmL]. Clinical Ophthalmology (2020). Medium credibility.

Discussion

Phacoemulsification as a cataract surgery technique was proposed over 40 years ago, and advances in surgical approaches and equipment have increased its safety and efficiency. However, post-operative ocular inflammation remains as a cause of visual impairment and pain. The degree of postoperative inflammation following cataract surgery is related to several surgery-dependent factors such as technique used, intraocular lens type, and to patient-dependent factors such as degree of iris pigmentation, and history of inflammatory disease, among others. Difluprednate is a prednisolone-derived molecule used for treating postoperative ocular inflammation and pain. Advantages of this formulation include dose uniformity and better bioavailability. Difluprednate was formulated as a stable oil-in-water emulsion to bring optimum dosage consistency. The pharmacokinetics of a single ocular instillation of generic 0.05% difluprednate emulsion (PRO-145) have been evaluated in a preclinical study in New Zealand white rabbits. PRO-145 penetrates different ocular tissues (conjunctiva, cornea and aqueous humor) and has a similar pharmacokinetic profile compared to currently commercially available difluprednate (Durezol ®, Alcon Laboratories, Inc. Fort Worth, TX, USA). It is distributed to the anterior and posterior segments via both trans-corneal and non-corneal absorption routes. Even though results in animal models cannot be extrapolated directly to administration in humans, the results of this study were consistent with other similar studies.

---

### Refractive surgery preferred practice pattern ® [^116XXiiN]. Ophthalmology (2023). High credibility.

Postoperative care — antibiotics, corticosteroids, intraocular pressure (IOP) monitoring, and pain control: Topical antibiotics are usually administered, and topical corticosteroids are generally started immediately after surgery and tapered over a period of days to weeks, and in some cases, months; mild transient elevations of IOP can commonly be managed with topical therapy, but close monitoring is essential because IOP will become elevated in a significant proportion of patients with prolonged corticosteroid use; postoperative pain is typically reduced by using a bandage contact lens and NSAID drops, some patients may benefit from oral analgesics, and small quantities of dilute topical anesthetic are sometimes used but warrant close supervision.

---

### Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery [^116YtGyQ]. Clinical Ophthalmology (2011). Low credibility.

Background

To compare the safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% (LE ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery.

Methods

Two randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies were conducted. Patients aged ≥ 18 years with a combined postoperative anterior chamber cells and flare (ACI) ≥ Grade 3 following uncomplicated cataract surgery participated in seven study visits. Patients self-administered either topical LE ointment or vehicle four times daily for 14 days. Efficacy outcomes included the proportion of patients with complete resolution of ACI and the proportion of patients with no (Grade 0) pain at postoperative day 8. Safety outcomes included the incidence of adverse events, ocular symptoms, changes in intraocular pressure and visual acuity, and biomicroscopy and funduscopy findings.

Results

Data from the two studies were combined. The integrated intent-to-treat population consisted of 805 patients (mean [standard deviation] age 69.0 [9.2] years; 58.0% female and 89.7% white). Significantly more LE ointment-treated patients than vehicle-treated patients had complete resolution of ACI (27.7% versus 12.5%) and no pain (75.5% versus 43.1%) at day 8 (P < 0.0001 for both). Fewer LE ointment-treated patients required rescue medication (27.7% versus 63.8%), and fewer had an ocular adverse event (47.2% versus 78.0%, P < 0.0001) while on study treatment. The most common ocular adverse events with LE ointment were anterior chamber inflammation, photophobia, corneal edema, conjunctival hyperemia, eye pain, and iritis. Mean intraocular pressure decreased in both treatment groups. Four patients had increased intraocular pressure ≥ 10 mmHg (three LE ointment and one vehicle) prior to rescue medication. Visual acuity and dilated funduscopy results were similar between the treatment groups, with the exception of visual acuity at visits 5 and 6, which favored LE ointment.

Conclusion

LE ointment was efficacious and well tolerated in the treatment of ocular inflammation and pain following cataract surgery.

---

### Diclofenac sodium (diclofenac) [^112SQivi]. FDA (2022). Medium credibility.

CLINICAL PHARMACOLOGY

Pharmacodynamics

Diclofenac sodium is one of a series of phenylacetic acids that has demonstrated anti-inflammatory and analgesic properties in pharmacological studies. It is thought to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins.

Animal Studies

Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

Pharmacokinetics

Results from a bioavailability study established that plasma levels of diclofenac following ocular instillation of two drops of Diclofenac sodium ophthalmic solution, 0.1% to each eye were below the limit of quantification (10 ng/mL) over a 4-hour period. This study suggests that limited, if any, systemic absorption occurs with Diclofenac sodium ophthalmic solution, 0.1%.

Clinical Trials

Postoperative Anti-Inflammatory Effects

In two double-masked, controlled, efficacy studies of postoperative inflammation, a total of 206 cataract patients were treated with Diclofenac sodium ophthalmic solution, 0.1% and 103 patients were treated with vehicle placebo. Diclofenac sodium ophthalmic solution, 0.1% was favored over vehicle placebo over a 2-week period for the clinical assessments of inflammation as measured by anterior chamber cells and flare.

In double-masked, controlled studies of corneal refractive surgery (radial keratotomy (RK) and laser photorefractive keratectomy (PRK)) patients were treated with Diclofenac sodium ophthalmic solution, 0.1% and/or vehicle placebo. The efficacy of Diclofenac sodium ophthalmic solution, 0.1% given before and shortly after surgery was favored over vehicle placebo during the 6-hour period following surgery for the clinical assessments of pain and photophobia. Patients were permitted to use a hydrogel soft contact lens with Diclofenac sodium ophthalmic solution, 0.1% for up to three days after PRK.

---

### Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two phase III clinical studies [^111f17fR]. Clinical Ophthalmology (2019). Medium credibility.

The clinical development program designed to evaluate the safety and efficacy of LE (submicron) gel 0.38% included two similarly designed, Phase III, randomized, vehicle-controlled trials, of LE gel 0.38% or vehicle instilled either BID or TID, for the treatment of postoperative inflammation and pain following cataract surgery with intraocular lens implantation. In both studies, LE gel 0.38% administered TID was safe and effective in the treatment of ocular inflammation and pain following cataract surgery, leading to the United States FDA approval of this new LE (submicron) gel formulation with TID dosing in February 2019 with the brand name of Lotemax ® SM. Herein, we report on integrated data for LE (submicron) gel 0.38% administered TID compared with vehicle from these two trials to provide a robust analysis of the efficacy, safety, and tolerability of LE gel 0.38% at this dosing regimen in the postoperative setting.

---

### Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction [^111cJJU6]. Clinical Ophthalmology (2012). Low credibility.

Ophthalmic bromfenac sodium sesquihydrate is a topically applied selective cyclooxygenase (COX)-2 inhibitor. It is similar to amfenac, except for a bromine atom at the C(4) of the benzoyl ring position, which markedly affects its in vitro and in vivo potency, extends the duration of anti-inflammatory activity, and enhances its inhibitory effect on COX-2 absorption across the cornea and penetration into ocular tissues. The United States Food and Drug Administration approved bromfenac in 2005 for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs), and among them bromfenac, could be even more effective than steroids at reestablishing the blood-aqueous barrier, as revealed by flare on slit-lamp examination and as quantitatively measured using ocular fluorophotometry. Similar to other NSAIDs, it has a role in inhibiting intraoperative miosis during cataract surgery. However, bromfenac also seems to be useful in other situations, such as refractive surgery, allergic conjunctivitis (not useful in dry eye), choroidal neovascularization, and even ocular oncology. No reports of systemic toxicity have been published and bromfenac has good topical tolerance with a low incidence of adverse effects.

---

### Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery [^114CWBvV]. American Journal of Ophthalmology (2011). Low credibility.

Purpose

To evaluate the efficacy and safety of twice-daily, preservative-free ketorolac 0.45% (Acuvail; Allergan, Inc, Irvine, California, USA) administration for treatment of inflammation and pain after cataract surgery.

Design

Prospective, randomized trial.

Methods

Two multicenter, double-masked studies randomized 511 cataract surgery patients (2:1) to receive twice-daily ketorolac 0.45% or vehicle in the operative eye for 16 days, beginning 1 day before surgery. The primary efficacy end point was the percentage of patients with a summed ocular inflammation score of 0 for anterior chamber cell and flare on postoperative day 14. The main secondary efficacy end point was the percentage of patients with no pain on postoperative day 1.

Results

On day 14, 52.5% of ketorolac patients and 26.5% of vehicle patients had an summed ocular inflammation score of 0 (P < .001). On day 1, 72.4% of ketorolac patients and 39.7% of vehicle patients had a pain score of 0 (P < .001). Median time to pain resolution was 1 day in the ketorolac group and 2 days in the vehicle group (P < .001). The percentage of ketorolac and vehicle patients who had a +3-line or more improvement in best-corrected visual acuity from baseline was 60.5% versus 44.0% on day 14 (P = 0.002). Overall, adverse events were more prevalent in the vehicle group than in the ketorolac group (48.5% vs 35.2%; P = 0.004). Burning or stinging (per a composite Medical Dictionary for Regulatory Activities) was reported by 1.5% of ketorolac patients and 0.6% of vehicle patients.

Conclusions

Twice-daily ketorolac 0.45% was well tolerated and effectively treated inflammation and pain following cataract surgery.

---

### First real-world, multicenter, post-marketing, retrospective study of dexamethasone intraocular suspension for inflammation after cataract surgery [^111TdwmK]. Clinical Ophthalmology (2022). Medium credibility.

Discussion

Phase 3 trials of intraocular DXM for the management of postoperative inflammation excluded certain patient types and clinical scenarios routinely encountered in real-world practice. This retrospective observational study was aimed to complement these trials with results from a heterogeneous real-world patient population treated by multiple surgeons. Although a variety of surgical interventions and concomitant medications were used in this study, including topical corticosteroids and NSAIDs, some patients (23.4% of eyes) received intraocular DXM alone for postoperative inflammation, and results overall were consistent with those from phase 3 clinical trials.

In the controlled clinical trials, concomitant anti-inflammatory medication was permitted only in rescue treatment. Use of rescue medication was uncommon in patients receiving intraocular DXM (eg, 10% by day 8 for the marketed dose in the placebo-controlled trial). In our analyses by concomitant medication, rates of ACC and ACF clearing were favorable for eyes treated with intraocular DXM alone as well as for eyes receiving other anti-inflammatory medications (Figure 2). Initiation of concomitant medication perioperatively or on day of surgery was common, perhaps reflecting clinicians' limited experience with intraocular DXM or their routine use of NSAIDs for pain and inflammation management.

In our study population, mean IOP at POD 1 was 18.6 mmHg and declined at later visits. Elevated IOP was spontaneously reported as an AE in 7 (1.3%) patients. These results accord with those in the placebo-controlled trial, in which increases of 10 mmHg or more from baseline were observed in 29% of patients treated with the currently recommended dose, but mean IOP did not exceed 21 mmHg at any assessment up to 30 days. In the active-control trial, a higher incidence of IOP increase was observed with intraocular DXM than with topical prednisolone (11.1% vs 3.6%). However, a post hoc analysis of pooled trial data found that risk did not significantly differ for intraocular DXM versus topical prednisolone. Between the two studies, 25 (8.9%) eyes treated with intraocular DXM received a topical IOP-lowering medication.

---

### Nepafenac (Ilevro) [^111CaVEW]. FDA (2025). Medium credibility.

14 CLINICAL STUDIES

In two double masked, randomized clinical trials in which patients were dosed daily beginning one day prior to cataract surgery, continued on the day of surgery and for the first two weeks of the postoperative period, ILEVRO®0.3% demonstrated superior clinical efficacy compared to its vehicle in treating postoperative pain and inflammation.

Treatment effect over vehicle for resolution of ocular pain occurred as early as Day 1 post-surgery. Treatment effect over vehicle for resolution of inflammation was significantly better than vehicle in both studies at Day 7 and Day 14 post-surgery.

---

### 0.2% betamethasone sodium phosphate: a multicenter, randomized, double-masked study to compare its ocular safety, tolerability, and efficacy to vehicle in cataract surgery subjects [^114bavVW]. Clinical Ophthalmology (2023). Medium credibility.

Introduction

Age-related cataract is a leading cause of visual impairment worldwide, with numbers expected to increase as the aging population increasesGlobally, 17 million people are blind and 94 million have vision impairment because of cataract;, the number of cataract surgeries is expected to reach 50 million by 2050. With millions of surgeries performed yearly worldwide, cataract surgery is generally deemed one of the safest surgical procedures, with very few serious postoperative complications.

Both ocular inflammation and pain are common post-cataract surgery. These are accepted and expected postoperatively, yet if left untreated they can lead to impaired vision and decreased patient satisfaction. Walters et al showed that in the early postoperative period, 70% to 85% of patients had anterior chamber cells, 50% to 65% of patients had anterior chamber flare, and 40% to 60% of patients reported ocular pain. The most common treatments for these complaints include both nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Steroids provide some advantages over NSAIDs-steroids produce a wider anti-inflammatory response than NSAIDs and are less expensive; however, they also produce an increased risk of intraocular pressure (IOP) elevation and their frequent dosing schedule may result in poor patient compliance and adherence. NSAID use alone, however, has been associated with corneal melts and ocular discomfort. In the US, it is common practice for ophthalmologists to use a combination of NSAIDs and corticosteroids, although the American Academy of Ophthalmology states NSAID use in postoperative cataract patients remains controversialand the increased positive effect of adding NSAIDs to topical corticosteroids may simply be the result of additional dosing. Corticosteroids, on the other hand, are a well-accepted effective treatment for ocular inflammation, The mechanism of action is similar among all corticosteroids: anti-inflammatory effects achieved through suppression of vascular endothelial cell adhesion molecules, cyclooxygenase I or II, and through cytokine expression.

---

### Opioids for ocular pain – A narrative review [^117VAxZq]. Pain Physician (2017). Low credibility.

Background

Refractive surgery is a common procedure, but may be associated with severe post-operative pain.

Objectives

To describe studies addressing the use of opioids for control of pain after ocular surgery, with an emphasis on refractive surgery.

Study Design

This is a narrative review of relevant articles on the physiology of corneal pain and the use of opioids for its treatment after surgery.

Setting

Single tertiary center.

Methods

A PubMed search was conducted for studies published from January 1985 to May 2015 on the physiopathology of corneal pain and opioid treatment of post-refractive surgical pain. Reviews, meta-analyses, and randomized clinical trials were included. Inclusion criteria focused on photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK).

Results

Authors found 109 articles through the search strategies. A total of 75 articles were included based on the inclusion criteria.

Discussion

Pain after ocular surgery is likely to be a multifactorial phenomenon. A combination of topical and systemic analgesics is used to treat post-operative pain after refractive surgery. Pain may be severe during the first 72 to 96 hours, depending on the surgical procedure. No studies were found that directly analyze the benefits of opioids after PRK, although they are routinely prescribed in some centers.

Limitations

This is a narrative review in contrast to a systematic review and did not include studies indexed in databases other than PubMed.

Conclusions

Although opioids are used for the short-term treatment of post-operative pain in refractive surgery, their benefits and risks should be properly evaluated in randomized clinical trials before their use can be safely advised.

Key Words

Photorefractive keratectomy, in situ keratomileusis, pain, analgesia, opioid, codeine, review.

---

### Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two phase III clinical studies [^117K11nR]. Clinical Ophthalmology (2019). Medium credibility.

Purpose

To evaluate the efficacy and safety of a submicron formulation of loteprednol etabonate (LE) gel 0.38% instilled three times daily (TID) compared with vehicle for the treatment of inflammation and pain following cataract surgery with intraocular lens implantation, integrated across two multicenter, double-masked, randomized, parallel-group, Phase III studies.

Patients and methods

Subjects ≥ 18 years of age with anterior chamber (AC) cells ≥ grade 2 (6–15 cells) on day 1 after cataract surgery were randomized to receive 1 drop of LE gel 0.38% TID, twice daily (not reported/analyzed herein), or vehicle instilled in the study eye for 14 days. Primary endpoints were the proportion of subjects with resolution of AC cells and grade 0 (no) pain at postoperative day 8. Safety outcomes included adverse events (AEs), ocular signs, fundoscopy results, visual acuity, intraocular pressure (IOP), and tolerability (drop comfort and ocular symptoms).

Results

The integrated intent-to-treat population included 742 subjects (LE gel 0.38% TID, n = 371; vehicle, n = 371). Significantly more subjects in the LE gel 0.38% TID group compared with the vehicle group had complete resolution of AC cells (29.6% vs 15.1%) and grade 0 pain (74.4% vs 48.8%) at day 8 (P < 0.0001 for both). LE gel 0.38% TID was safe and well tolerated, with only 1 LE-treated subject experiencing an IOP elevation ≥ 10 mm Hg. Most treatment-related AEs were mild and occurred less frequently with LE gel 0.38% than with vehicle. The majority (> 75%) of subjects in each treatment group reported no drop discomfort. There were no reports of blurred vision with LE gel.

Conclusion

The results of this integrated analysis indicate that LE (submicron) gel 0.38% administered TID is safe and effective for the treatment of ocular inflammation and pain following cataract surgery, with minimal risk of IOP elevation.

---

### Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution [^114tQzbF]. Clinical Ophthalmology (2009). Low credibility.

Recently, several new ophthalmic NSAID products have been introduced for commercial use in the United States. The purpose of this review is to briefly overview the ophthalmic NSAIDs currently in use and to discuss the management of postoperative ocular inflammation and pain following cataract surgery with a particular focus on bromfenac ophthalmic solution 0.09%. Bromfenac ophthalmic solution 0.09% is indicated for the reduction of ocular pain and inflammation following cataract surgery. Studies have shown that bromfenac ophthalmic solution 0.09% has equivalent efficacy to the other topical NSAIDs in reducing postsurgical inflammation and controlling pain. The unique chemical structure of bromfenac makes it both a potent inhibitor of the COX-2 enzyme and a highly lipophilic molecule that rapidly penetrates to produce early and sustained drug levels in all ocular tissues. Clinically, these pharmacokinetic features are manifested in a rapid reduction of postsurgical inflammation and pain with bid dosing. Bromfenac ophthalmic solution 0.09% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.

---

### A randomized, prospective, observer-masked study comparing dropless treatment regimen using intracanalicular dexamethasone insert, intracameral ketorolac, and intracameral moxifloxacin versus conventional topical therapy to control postoperative pain and inflammation in cataract surgery [^116wPYZ7]. Clinical Ophthalmology (2023). Medium credibility.

Introduction

Eyedrops are a well-established, convenient, and noninvasive method for delivering anti-infective and anti-inflammatory drugs to the anterior segment of the eye following cataract surgery. However, topical drug delivery is associated with several limitations that can adversely affect visual outcomes and patient satisfaction.

Poor drug bioavailability is a major concern associated with eye drops. It has been estimated that less than 5% of the drug reaches intraocular tissues, mainly due to the precorneal loss following topical administration, the corneal-epithelial barrier, and drug loss through the conjunctival-scleral route. Topical eyedrop administration, by nature of its intermittent application, also results in variable drug concentration over time, with peak concentrations (immediately after instillation) potentially increasing the risk for side effects, and trough concentrations (before the next instillation) potentially producing an insufficient pharmacologic effect. In addition, topical medications are preserved, which can have a deleterious effect on the ocular surface, degrading quality of vision and patient satisfaction with cataract surgery.

Diligent patient compliance with postoperative medications is paramount to ensure optimal outcomes following cataract surgery. However, the noncompliance rate for ocular medications has been shown to be approximately 30%. A compliance monitoring study in cataract and glaucoma patients reported a low adherence rate, with almost 50% of the doses omitted. An et al documented that as high as 92% of post-cataract patients exhibited inappropriate drop administration, such as missing the eye, instilling too many drops, contaminating the bottle tip by touching the ocular surface, and failing to wash their hands before administration. In the elderly, poor dexterity, tremors, and poor near vision all add to the difficulty of instilling drops. Additionally, tapering regimens may be complex for some patients to understand, especially in the context of dementia or cognitive difficulties. The high cost of the medications is potentially another reason for patient noncompliance.

---

### Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain [^115cxJCr]. BMC Ophthalmology (2024). Medium credibility.

Background

Nowadays, corneal refractive surgery offers a choice of procedures, such as laser-assisted in situ keratomileusis (LASIK), femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK), and small-incision lenticule extraction (SMILE), all of which are associated with high indices of efficacy and safety. Nonetheless, dry eye disease (DED) is the most common complication after corneal refractive surgery and one of the leading causes of patient dissatisfaction. Although DED generally occurs transiently in the early postoperative period, it may also develop into a chronic condition, and approximately 18–41% of patients develop chronic DED for more than 6 months. It becomes more worrisome when combined with ocular pain.

Conventional artificial tears, such as sodium hyaluronate, are the first-line therapy for patients with DED and temporarily alleviate dry eye symptoms owing to their water-retentive properties. However, its therapeutic mechanism is single; it may not be sufficient enough to treat DED following refractive surgery. In addition, patients with DED combined with ocular pain were more likely to show an incomplete response to conventional artificial tears than those without ocular pain. Anti-inflammatory drugs, such as topical glucocorticoids and cyclosporine, are recommended for patients who are unresponsive to treatment with conventional artificial tears. However, long-term use of topical glucocorticoids can lead to complications such as steroid-induced glaucoma and cataracts.

---

### Loteprednol etabonate (inveltys) [^112wDAd3]. FDA (2024). Medium credibility.

14 CLINICAL STUDIES

Clinical efficacy was evaluated in 2 multi-centered, randomized, double-masked, placebo-controlled trials in which patients with an anterior cell grade greater than or equal to "2" (a cell count of 6 or higher using a slit-lamp biomicroscope) after cataract surgery were assigned to INVELTYS or placebo (vehicle) following surgery (NCT # 02163824 and NCT # 02793817). One to two drops of INVELTYS or vehicle was self-administered twice a day for 14 days, beginning the day after surgery. Complete resolution of inflammation (a cell count of 0 maintained through day 15 without rescue medication) and complete resolution of pain (a patient-reported pain grade of 0 maintained through day 15 without rescue medication) was assessed 4, 8, and 15 days post-surgery. In the intent-to-treat analysis of both studies, a significant benefit was seen in the INVELTYS -treated group for complete resolution of ocular inflammation at Days 8 and 15, and complete resolution of pain at Days 4, 8, and 15, when compared with placebo. The consolidated clinical trial results are provided below.

Figure 1 Consolidated Clinical Trial Data: Percent of Patients with Complete Resolution of Anterior Chamber Cells (Cell Count = 0) at Days 8 and 15

* p-values < 0.01 for treatment comparisons

Figure 2 Consolidated Clinical Trial Data: Percent of Patients Who Were Pain Free at Days 4, 8, and 15

* p-values < 0.01 for treatment comparisons

---

### Bromfenac ophthalmic solution 0.09% (xibrom) for postoperative ocular pain and inflammation [^113nj9au]. Ophthalmology (2007). Low credibility.

Objective

To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.09% (Xibrom) for the treatment of postoperative inflammation and reduction of ocular pain in subjects who have undergone cataract extraction (CE).

Design

Two phase III, multicenter, randomized, double-masked, parallel, placebo-controlled clinical trials were conducted under a common protocol. Data were pooled for analyses.

Participants

Five hundred twenty-seven subjects were sequentially assigned, according to a computer-generated randomization list (2:1), to bromfenac (n = 356) or a placebo (n = 171).

Intervention

Subjects who underwent cataract surgery without prior antiinflammatory treatment with a postsurgical Summed Ocular Inflammation Score (SOIS) of ≥ 3 were treated with either bromfenac or the placebo, instilled twice daily for 14 days in the study eye, and observed for an additional 14 days for safety evaluation.

Main Outcome Measure

Cleared ocular inflammation with a SOIS of 0 (cells ≤ 5 and absence of flare after 14 days of treatment). Secondary outcomes included time to resolution of ocular inflammation, time to resolution of ocular pain, proportion of subjects with photophobia, and ocular adverse events.

Results

Baseline characteristics were comparable between groups for age, gender, and race. The baseline mean SOIS was 3.7 in both groups. A greater proportion of bromfenac (64.0%) than placebo subjects (43.3%) achieved complete clearance of ocular inflammation at study day 15 (P < 0.0001). The effect of bromfenac on clearance of ocular inflammation was as early as study day 3 after initiation of treatment, compared with the placebo (8.4% vs. 1.2%, P = 0.0012). The median time to resolution of ocular pain was 2 days (bromfenac) versus 5 days (placebo) (P < 0.0001). Numbers of most ocular adverse events were lower for the bromfenac group than for the placebo group. Eye irritation was reported in a lower percentage of subjects for bromfenac (2.5%) versus placebo (4.7%), as were burning and stinging (1.4% vs. 2.5%), and photophobia (2.0% vs. 11.1%).

Conclusions

Bromfenac ophthalmic solution 0.09% effectively and rapidly cleared ocular inflammation and reduced ocular pain after CE. There were no serious ocular adverse events, and fewer adverse events were reported for the bromfenac group.

---

### Survey of postoperative pain in photorefractive keratectomy using topical versus oral nonsteroidal anti-inflammatory drugs [^113XYcnH]. Clinical Ophthalmology (2020). Medium credibility.

Discussion

Despite the safety and efficacy of PRK as a method of refractive surgery, postoperative pain remains a significant and potentially limiting side effect. The cornea is one of the most densely innervated tissues in the body. Postoperative PRK pain is thought to occur due to the release of inflammatory mediators following the removal of the epithelial layer, which causes increased sensory nerve excitability. While the magnitude of refractive error and ablation depth has not been found to correlate with pain levels, subjective preoperative dry eye symptoms are associated with higher postoperative pain scores. The acute pain phase may begin shortly after the procedure and continues until re-epithelization at approximately day five. Our findings suggest a consistent and identifiable trend in the postoperative pain course. Both groups experienced the highest levels of pain on days two and three (24–72 hours post-procedure), which then decreased through day five. The average peak pain level was noted to be 4.18 and 3.9 on days two and three respectively. This finding is consistent with previous studies, which found that pain peaks approximately 24–36 hours after the procedure.-Our data, however, demonstrate that peak pain levels often persist for up to 72 hours (day 3). These findings provide additional information about peak pain levels and timing after PRK, which may be valuable in counseling prospective patients as well as the care team.

---

### ACSM expert consensus statement: injury prevention and exercise performance during cold-weather exercise [^112GA1dD]. Current Sports Medicine Reports (2021). High credibility.

Treatment — corneal pain and ocular surface management: Close eyes and rest until pain eases, cool gently through the closed eyelid, and use oral analgesics such as paracetamol 1 g, four time a day; if available, administer topical lubricant and apply nonsteroidal anti-inflammatory eyedrops such as diclofenac 0.1%. Topical anesthetics slow corneal recovery and should not be used outside emergency situations, and topical antibiotics may be considered in severe cases to prevent infection. Cycloplegic eye-drops (cyclopentolate 1%) may relieve pain but impair vision.

---

### Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery [^1126ygv7]. Clinical Ophthalmology (2014). Low credibility.

Review of efficacy studies

LE has been available for clinical use for more than a decade. There are three formulations of Lotemax preparations: suspension, gel, and ointment. No randomized comparative controlled study of Lotemax ointment has been published thus far. All clinical studies have investigated the efficacy of Lotemax ophthalmic suspension or the gel rather than the ointment. Loteprednol has been shown to be efficacious in the treatment of inflammation related to seasonal allergic conjunctivitis, giant papillary conjunctivitis, anterior uveitis, dry eye, and cataract surgery. A comprehensive literature review including the keywords "loteprednol etabonate" and "efficacy" (PubMed search 1991–2013) resulted in 103 articles, of which only four were related to corneal transplant surgery. However, corneal transplant surgery has evolved like medication options, so researchers have looked at endothelial survival after Descemet's stripping automated endothelial keratoplasty (DSAEK). This study reported switching some patients to LE during the course of postoperative treatment. The authors approach was to use LE as an alternative to prednisolone acetate. The primary focus of other studies looking at the efficacy of LE was where it is used to treat ocular inflammation, the safety and level of pain control following cataract surgery, and other conditions unrelated to PK surgery (such as vernal or seasonal allergic conjunctivitis). There seems to be a change in practice patterns where corneal surgeons use LE as an option for post-PK and -DSAEK patients. At the same time, we are seeing a movement away from preserved drops in the clinical setting, so the use of LE ointment is occurring, but we are unable to provide any direct citations on the efficacy or safety of Lotemax ointment in treatment of inflammation and pain following PK. However, Lotemax suspension or gel comparative efficacy studies on the control of inflammation and pain following other forms of intraocular surgeries can be indirectly attributed to Lotemax ointment, as it contains the same active ingredient without BAK preservative.

---

### Bromfenac sodium (bromfenac) [^114GugYU]. FDA (2012). Low credibility.

Clinical Trials

Clinical efficacy was evaluated in two randomized, double-masked, vehicle-controlled U.S. trials in which subjects with a summed ocular inflammation score ≥ 3 after cataract surgery were assigned to bromfenac ophthalmic solution or vehicle in a 2:1 ratio following surgery. One drop of bromfenac ophthalmic solution or vehicle was self-instilled in the study eye twice a day for 14 days, beginning the day after surgery. The primary endpoint was reduction of ocular inflammation (to trace inflammation or clearing) assessed 14 days post-surgery using a slit lamp binocular microscope. In the intent-to-treat analyses of both studies, a significant effect of bromfenac ophthalmic solution on ocular inflammation after cataract surgery was demonstrated (62 to 66% vs. 40 to 48%). An additional efficacy end point was the time required for resolution of ocular pain in subjects who reported pain. Overall, only 20% of the patients undergoing cataract surgery in these trials had pain on the first day after surgery. In these patients, the bromfenac ophthalmic solution group demonstrated a statistically significant difference in median time to resolution of ocular pain of 2 days compared to 4 days for patients receiving vehicle.

---

### Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two phase III clinical studies [^111vVLng]. Clinical Ophthalmology (2019). Medium credibility.

Introduction

The use of topical corticosteroids following cataract surgery is routine for the management of postoperative inflammation and pain. Potential side effects of concern with the postsurgical use of ocular corticosteroids include increased intraocular pressure (IOP), susceptibility to infection, and delayed wound healing.–Loteprednol etabonate (LE) is a retrometabolically designed topical corticosteroid that was engineered via modification of prednisolone in order to achieve the desired anti-inflammatory effect followed by rapid metabolism to inactive metabolites. This approach aims to preserve the beneficial corticosteroid effects while reducing the potential for adverse reactions. LE has been shown to pose a low risk of clinically significant IOP elevations with both short-term and long-term use and has demonstrated lower rates of clinically significant IOP elevation in comparison to prednisolone acetate or in comparison to dexamethasone/tobramycin when used in combination with tobramycin. The anti-inflammatory effects of LE across a range of clinical ocular conditions and its reduced potential to increase IOP have been reviewed in detail elsewhere.

The first ophthalmic formulation of LE, a 0.5% suspension, was approved in 1998 for the treatment of postoperative inflammation and pain following ocular surgery as well as for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye (eg, allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis).LE ophthalmic suspension 0.5% administered four times daily (QID) demonstrated safety and efficacy for the management of postoperative inflammation and exhibited similar efficacy with less fluctuation in IOP assessments compared with prednisolone for reducing postsurgical ocular inflammation. Subsequently, a nonsettling ophthalmic gel formulation of LE 0.5% containing micron-sized drug particles was approved by the United States Food and Drug Administration (FDA) in September 2012.–This gel formulation provides consistent, uniform dosing and eliminates the requirement to shake to resuspend the drug prior to instillation. The safety and efficacy of LE ophthalmic gel 0.5% QID in reducing inflammation and pain following cataract surgery have been demonstrated in a number of studies both in comparison to vehicle and to difluprednate 0.05%.–

---

### 0.2% betamethasone sodium phosphate: a multicenter, randomized, double-masked study to compare its ocular safety, tolerability, and efficacy to vehicle in cataract surgery subjects [^117Sv5G2]. Clinical Ophthalmology (2023). Medium credibility.

Assessments

Evaluations of efficacy included biomicroscopic examinations for anterior chamber cells and flare and a Visual Analog Scale (VAS) of ocular pain as recorded in the subject diary. The primary efficacy endpoint was the proportion of subjects who had cleared ocular inflammation (anterior chamber cell score of 0) at Day 15. The VAS was used to evaluate eye pain/discomfort at screening Visit 1 (Day -14 to Day -2) and at Visit 3 through Visit 7 (Day 1 through Day 32); scoring from 0 to 100 using a mark on a 100 mm line (0 = absent; 100 = maximum). Pain was evaluated before each study drug dose using a pain scale that subjects completed at home. In addition to the VAS, subjects were asked to assess their study eye pain level prior to each study drug dose via a diary at home. For this, VAS descriptive FACES were combined with the dosing diary. Table 1 shows the grading scales for inflammation, while Table 2 and Figure 1 show the VAS and grading scale used to analyze ocular pain.

Table 1
Anterior Chamber Cell and Flare Grading

Table 2
Ocular Pain Scale

Figure 1
VAS descriptive faces.

A worsening of 3 lines or more in logMAR score in the study eye from baseline or any prior visit was deemed an adverse event (AE) and noted as such. An increase from baseline or any prior study visit of 10 mmHg or more in IOP in the study eye was also considered an AE. An IOP of 30 mmHg or higher were reported as a serious AE (SAE).

Safety Analyses

The safety endpoints of the study were AEs, BCVA, IOP, and biomicroscopic and ophthalmoscopic findings. Objective signs of ocular inflammation, including chemosis, bulbar conjunctival injection, ciliary injection, corneal edema, and keratic precipitates, were evaluated according to a 0–3 grading scale.

The protocol was in compliance with Good Clinical Practices (GCP) and the Declaration of Helsinki (1996) and in accordance with applicable Institutional Review Board (IRB) regulations [United States 21 Code of Federal Regulations (US 21 CFR) part 56.103]; Advarra IRB (6100 Merriweather Dr, Ste. 600, Columbia, MD) granted IRB approval. Study participants gave informed consent prior to initiation of any study-related procedures. The study was performed in compliance with informed consent regulations (US 21 CFR part 50).

---

### Retrospective study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation after cataract and corneal surgery [^112HQHg8]. Clinical Ophthalmology (2022). Medium credibility.

Discussion

Inflammation management is a vital part of an eye surgeon's post-surgery recovery plan for patients undergoing cataract or corneal surgeries. Topical administration of corticosteroids has long been the standard method for combating inflammation following eye surgery; however, it is not without its drawbacks. Topical steroid administration has been found to potentially delay corneal epithelial healing, as well as reduce the immunological competence of the eye. In addition, many patients struggle to adhere to the complex topical steroid regimens, preventing them from realizing the full recovery potential that the regimens were designed to deliver. Dextenza is an alternative method for corticosteroid delivery to ocular tissues post cataract or corneal surgery. This intracanalicular insert is designed to deliver preservative free dexamethasone to the ocular surface for up to thirty days, mitigating the effects of volatile patient compliance. Previous studies exploring the safety and efficacy of Dextenza, by monitoring adverse events, ocular pain and inflammation found significant reductions in inflammation and ocular pain in study groups that received Dextenza. This study differs from the previous studies exploring Dextenza, by assessing its safety and effectiveness in patients who have undergone corneal transplantation surgeries.

The Dextenza insert was evaluated for both its effectiveness and safety as a corticosteroid delivery system in the post-operative recovery regimens of 18 patients who underwent cataract extraction, and 6 patients who underwent corneal surgeries. The goal was to evaluate this therapy as adjunctive to topical therapy in order to decrease the total drop burden experienced by patients. Dextenza was found to be effective in reducing AC inflammation following cataract or corneal surgery. In the cataract surgery arm, 17 of the 18 patients who underwent cataract extraction had AC cell grades equal to 0 between 2 and 6 weeks post-cataract surgery, indicating that no AC cells were visualized in those patients. One of the patients had an AC cell grade of 0.5+ (less than five cells visualized in the AC),3-months post-cataract surgery. In the corneal surgery arm, all examined patients had AC cell grades equal to 0 at the 1 week post-corneal surgery time point. None of the patients in the cataract or corneal surgery arms showed evidence of AC flare from the first post-surgery day, and none of the patients experienced rebound inflammation.

---

### Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain [^116PmXAM]. BMC Ophthalmology (2024). Medium credibility.

Conclusions

In general, cyclosporine not only alleviates ocular pain and dry eye symptoms and signs in post-refractive surgery DED patients with ocular pain but also effectively controls ocular inflammation. Therefore, cyclosporine may be an effective alternative treatment for post-refractive surgery in patients with DED and ocular pain.

---

### Nepafenac (Nevanac) [^116NpesN]. FDA (2024). Medium credibility.

14 CLINICAL STUDIES

In two double-masked, randomized clinical trials in which patients were dosed 3 times daily beginning 1 day prior to cataract surgery, continued on the day of surgery and for the first 2 weeks of the postoperative period, NEVANAC 0.1% demonstrated superior clinical efficacy compared to its vehicle in treating postoperative pain and inflammation.

Patients treated with NEVANAC®0.1% were less likely to have ocular pain and measurable signs of inflammation (cells and flare) in the early postoperative period through the end of treatment than those treated with its vehicle.

For ocular pain in both studies, a significantly higher percentage of patients (approximately 80%) in the nepafenac group reported no ocular pain on the day following cataract surgery (Day 1) compared to those in the vehicle group (approximately 50%).

Results from clinical studies indicated that NEVANAC 0.1% has no significant effect upon IOP; however, changes in IOP may occur following cataract surgery.

---

### Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery [^116YUh3b]. Journal of Cataract and Refractive Surgery (2007). Low credibility.

Purpose

To determine whether nepafenac ophthalmic suspension 0.1% decreases the incidence and severity of inflammation and pain after cataract surgery with posterior chamber intraocular lens implantation.

Setting

Twenty-one ophthalmology clinics in the United States.

Methods

A randomized double-blind vehicle-controlled trial was conducted in which adult patients were randomly assigned to receive nepafenac 0.1% or vehicle beginning 1 day before surgery and continuing on the day of surgery (day 0) for 14 days. Patients were evaluated on days 1, 3, 7, and 14. The primary efficacy variable was the percentage of patients cured at day 14 (cure defined as aqueous cells score + aqueous flare score = 0). Other efficacy variables included percentage of patients who were pain free at all visits and aqueous cells, flare, and cells plus flare scores.

Results

The mean age of the 476 patients (243 nepafenac, 233 vehicle) was 70 years (range 27 to 93 years). At day 14, 152 patients (62.6%) in the nepafenac group and 40 (17.2%) in the vehicle group were cured (P < .0001). A higher percentage of patients in the nepafenac group was pain free at all visits (P < .0001). Throughout the study, most nepafenac-treated patients were pain free (83.1% to 93.0%) compared with less than half the vehicle-treated patients (41.6% to 46.4%). The nepafenac group had lower mean aqueous cells, flare, and cells plus flare scores at all visits (P < .0001). No treatment-related ocular adverse events occurred in either group.

Conclusion

Nepafenac ophthalmic suspension 0.1% was safe and effective for preventing and treating ocular inflammation and pain associated with cataract surgery.

---

### Bromfenac (bromday) [^111wHCps]. FDA (2010). Low credibility.

2 DOSAGE AND ADMINISTRATION

Instill one drop into the affected eye(s) once daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-surgery (2.1).

2.1 Recommended Dosing

For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of Bromday ophthalmic solution should be applied to the affected eye(s) once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.

2.2 Use with Other Topical Ophthalmic Medications

Bromday ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

---

### Comparison of subconjunctival triamcinolone with topical prednisolone for routine anti-inflammatory prophylaxis in manual small incision cataract surgery: a single-center, randomized controlled trial pilot protocol [^115KqkBS]. Clinical Ophthalmology (2025). Medium credibility.

AC Inflammation

A participant with an inflammation score of 5 or more (cell + flare) at any visit is examined by the unmasked evaluating ophthalmologist who determines the allocation group. Participants in group 1 are treated by doubling the frequency of PA administration based on the current dosing at the time of presentation. For example, if a participant presents during week 2 with pain and blurred vision and has score of 5 (cell + flare), the PA dose would be increased from three times daily to six times daily. Tapering would proceed by 1 drop per week. Follow ups are scheduled weekly until drops are discontinued. Participants in group 2 are started initially on PA four times daily, tapering 1 drop per week for a total of 4 weeks. Follow up is scheduled weekly until drops are discontinued. In all cases, persistence of the same level or greater inflammation from one visit to the next are addressed by the PI. In cases of persistence of an inflammation score of 5 or more for 1 week, the PI will determine additional treatment and submit an adverse event report to the Ethics Committee.

Corneal Edema

A participant with grade 3 corneal edema is examined by the unmasked evaluating ophthalmologist who determines the allocation group. Treatment and reporting follow the protocol for AC inflammation above but with a threshold of grade 3 corneal edema for more than one visit and for more than one week requiring follow up by the PI and reporting to the Ethics Committee.

Clinical Macular Edema

ME is suspected in a participant with a CDVA of 20/40 or worse at the 6- or 12-week visit or with a subjective perception of visual impairment at any time during the study. Upon presentation, the unmasked evaluating ophthalmologist will obtain SD-OCT. Confirmation of clinical ME is a CDVA of 20/40 or worse and central cystic spaces or central subfield thickness of 320 µm on SD-OCT. Confirmed ME is treated with topical bromfenac 0.09% (Ocuflam MedPharma, Guatemala) twice daily for 4 weeks. Follow up is scheduled 4 weeks following presentation for ophthalmic exam and repeat SD-OCT. Persistent ME at the subsequent visit is treated with 1.0 mL of peribulbar TA 40 mg/mL (4 mg) and a follow up is scheduled for 4 weeks. Persistent ME at that second follow up visit is treated at the discretion of the consulting clinical retinal specialist. The PI will submit an adverse event report to the Ethics Committee for persistent ME for more than 6 consecutive months.

---

### Evaluating a sustained-release dexamethasone insert as adjunctive therapy for inflammation and pain post-corneal transplantation [^111geWVi]. Clinical Ophthalmology (2024). Medium credibility.

Materials and Methods

This randomized, controlled, prospective study encompassed 30 eyes of 30 patients who underwent PKP, DSEK and DMEK procedures in a private practice setting by N.F and S.N between October 2020 and January 2022. Institutional review board approval was obtained by the WCG Institutional Review Board and written informed consent from all patients was obtained before beginning any study-related procedures. This study complied with the declaration of Helsinki.

Patient Grouping

The patients were divided into 3 groups based on the corneal transplantation method they underwent, which was determined based on each patient's ocular characteristics as well as their indication for surgery. Once the surgical method was established, patients in each group were randomly assigned to the treatment arm or the control arm using a 1:1 randomization ratio. Patients in the treatment arm received Dextenza immediately prior to their corneal transplantation surgery. Patients in the control group received nothing (no Dextenza) prior to their corneal transplantation surgery (Figure 1). All patients were followed up for 90 days following the corneal transplant procedure.

Figure 1
Randomization flow chart depicting the allocation of participants within our study. Participants were first enrolled and then placed into the PKP, DSEK, or DMEK groups based on their ocular characteristics and surgical indications. Within each of these groups, participants were randomized to either the Dextenza or control arm. The numbers indicate the participants at each stage, including those lost to follow up or excluded for specific reasons mentioned.

Study Metrics

Patient eligibility was determined at the screening visit where demographic data and medical history were recorded, a dilated ophthalmic examination was performed, and baseline measurements were obtained. IOP was measured using a Goldmann applanation tonometer. The presence of anterior chamber (AC) cell and flare, used as a marker for AC inflammation, was assessed at a slit lamp, and graded from 0 to 4+ using the standardization of uveitis nomenclature (SUN) working group grading scheme. Best corrected distance visual acuity (BCDVA) was measured at a distance of 4 meters using an early treatment diabetic retinopathy study (ETDRS) chart. Ocular pain was assessed by visual analogue scale (VAS) using a numerical rating scale from 0–100, where 0–39 = mild pain, 40–69 = moderate pain, and 70–100 = severe pain. These measurements were obtained, and adverse events were recorded at all follow up visits which were scheduled for 1 day, 7 days, 30 days, 60 days, and 90 days following the corneal transplant procedure.

---

### Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two phase III clinical studies [^116B2tnY]. Clinical Ophthalmology (2019). Medium credibility.

At any time during the study, subjects could be placed on anti-inflammatory rescue medication at the investigator's discretion. Subjects who required anti-inflammatory rescue medication discontinued study treatment and were considered treatment failures but were followed until the end of the study. Intracameral injection of antibiotic at the end of cataract surgery and/or the use of perioperative topical antibiotics (not combined with a steroid) was permitted at the discretion of the investigator. Subjects using topical antibiotics were instructed to instill the topical antibiotic at least 15 mins before administration of study treatment.

Efficacy assessments were performed on postoperative days 3 (visit 4), 8 (visit 5), 15 (visit 6), and day 18 (visit 7). At each site, AC cells and AC flare were evaluated by the same investigator, whenever possible, using a 1.0 mm × 1.0 mm high-power-field slit beam and graded on a 5-point scale (cells: 0 = no cells, 1 = 1–5 cells, 2 = 6–15 cells, 3 = 16–30 cells, 4 = > 30 cells; flare: 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe), with complete resolution of AC cells defined as a grade of 0 (ie, no cells observed). Subjects assessed and graded ocular pain (defined as foreign body sensation, stabbing, throbbing, or aching) on a 6-point scale (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe).

---

### Postoperative pain after cataract surgery [^111wMing]. Journal of Cataract and Refractive Surgery (2013). Low credibility.

Cataract extraction surgery is the most common surgical procedure, but knowledge of postoperative pain related to cataract surgery is sparse. In this systematic review, the incidence, prevalence, and management of pain after phacoemulsification surgery were identified using PubMed and Scopus. Selected studies were restricted to randomized controlled trials with interventions on postoperative inflammation and pain. Data from 105 articles were extracted and 21 studies met the final inclusion criteria. Most studies reported no or only mild postoperative pain, but some reported moderate and severe pain and pain lasting several weeks. The interventions consisted of drug therapy including topical nonsteroidal antiinflammatory drugs, corticosteroids, paracetamol, perioperative intraocular injections, eye pads used after surgery, and various surgical techniques. The reviewed literature indicates that cataract surgery is associated with significant postoperative pain in some patients, who should be provided with appropriate counseling and pain treatment.

---

### Cataract in the adult eye preferred practice pattern [^114JWEKb]. Ophthalmology (2022). High credibility.

Cataract postoperative medications — topical antibiotics for infection prophylaxis and topical corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) for CME prophylaxis are used, and corticosteroids and NSAIDs are also used for inflammation control; however, there is insufficient high-level evidence to compare these interventions, making it the decision of the operating surgeon to use one or both classes. Complications include elevated intraocular pressure (IOP) with corticosteroids, allergic reactions to antibiotics, and rare significant corneal reactions (epithelial defects and stromal ulceration and melting) with topical ocular NSAID use.

---

### Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery [^114N5edo]. Clinical Ophthalmology (2019). Medium credibility.

While effective in managing both pain and inflammation, use of topical corticosteroids poses certain potential risks, including IOP elevation, delayed wound healing, and cataract formation.–Steroid-induced IOP elevation is a particular concern in glaucoma subjects, as recent studies suggest that eyes diagnosed with primary open-angle glaucoma (POAG) have decreased trabecular meshwork (TM) thickness and increased TM stiffness when compared to healthy eyes. They are therefore more susceptible to IOP spikesand the subsequent decrease in aqueous outflow through the TM related to corticosteroid use.

Loteprednol etabonate (LE) is a topical corticosteroid approved by the FDA for postoperative inflammation and pain following ocular surgery and is marketed as a suspension, ointment, a gel formulation at a concentration of 0.5%, and most recently, a gel formulation at a concentration of 0.38%. The recommended dosing frequency for LE gel 0.5% is one to two drops into the conjunctival sac of the affected eye four times daily beginning the day after surgery and continuing throughout the first 2 weeks of the postoperative period. The LE molecule was specifically developed using retrometabolic drug design, with the goal of an improved safety profile relative to other corticosteroid compounds. The LE molecule differs from other ocular corticosteroids by having an ester rather than a ketone group at the carbon 20 position. By design, LE undergoes rapid conversion into inactive, nontoxic metabolites after binding to glucocorticoid receptors, thereby allowing for localized, controlled suppression of ocular inflammation with a limited potential for causing unwanted effects.–Use of steroids such as LE in the glaucoma setting is particularly important vis a vis limiting the potential for steroid-induced IOP increase in this already vulnerable population. The safety and anti-inflammatory efficacy of LE gel 0.5% have been demonstrated in various ocular surgery settings including following cataract surgery,–LASIK/PRK, and Descemet membrane endothelial keratoplasty.

---

### Plasma pharmacokinetic parameters of dexamethasone following administration of a dexamethasone intracanalicular insert in healthy adults [^112mHZgQ]. Clinical Ophthalmology (2021). Medium credibility.

Introduction

Corticosteroid eye drops have long been the standard of care for many ophthalmic conditions including postoperative pain and inflammation, and ocular surface diseases such as dry eyeand allergic conjunctivitis. While therapeutically beneficial, topical corticosteroids may be associated with several ocular complications including glaucoma, posterior subcapsular cataract, corneal thinning, infection, and preservative toxicity. In addition, barriers to effective therapy with ophthalmic drops generally include noncompliance, poor self-administration technique, and even accidental injury.

To address these problems, an intracanalicular insert has been developed which delivers dexamethasone to the surface of the eye for up to 30 days (Dextenza ® [dexamethasone ophthalmic insert] 0.4 mg, for intracanalicular use; Ocular Therapeutix, Bedford, MA). The insert comprises a biodegradable crosslinked synthetic hydrophilic polyethylene glycol-based hydrogel designed to deliver a tapering dose of preservative-free dexamethasone to the surface of the eye. As the insert is administered by the physician, there are no compliance issues and patients do not need to touch their face or eye to receive the medication. Following hydration, the insert consists of mostly water which contributes to its biocompatibility, allowing it to be used in the eye with low potential for inflammation or rejection. As the hydrogel gradually biodegrades, there is no need for removal. The dexamethasone hydrogel insert is fluorescein-conjugated to aid with visualization.

Large placebo-controlled studies have demonstrated the efficacy of the insert for alleviating inflammation and pain following cataract surgery, leading to FDA approval for the treatment of ocular inflammation and pain following ophthalmic surgery. Patients treated with the dexamethasone insert reported favorably on overall satisfaction, convenience and comfort. The insert has also been evaluated in Phase 3 studies for treating allergic conjunctivitis.

To address potential safety concerns from systemic absorption of dexamethasone in treated patients, the objective of this study was to evaluate the systemic pharmacokinetic (PK) parameters of dexamethasone following placement of a sustained-release insert in the canaliculus of the eyes of healthy subjects.